EP3114451A1 - Methods and devices for sample collection and sample separation - Google Patents
Methods and devices for sample collection and sample separationInfo
- Publication number
- EP3114451A1 EP3114451A1 EP15757840.2A EP15757840A EP3114451A1 EP 3114451 A1 EP3114451 A1 EP 3114451A1 EP 15757840 A EP15757840 A EP 15757840A EP 3114451 A1 EP3114451 A1 EP 3114451A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- sample
- separation material
- channel
- collection
- opening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000926 separation method Methods 0.000 title claims abstract description 281
- 238000000034 method Methods 0.000 title claims abstract description 79
- 239000000463 material Substances 0.000 claims abstract description 335
- 239000007788 liquid Substances 0.000 claims abstract description 63
- 230000037361 pathway Effects 0.000 claims description 168
- 210000001124 body fluid Anatomy 0.000 claims description 133
- 239000012530 fluid Substances 0.000 claims description 119
- 239000012528 membrane Substances 0.000 claims description 57
- 210000004369 blood Anatomy 0.000 claims description 43
- 239000008280 blood Substances 0.000 claims description 43
- 238000004891 communication Methods 0.000 claims description 34
- 230000009471 action Effects 0.000 claims description 20
- 238000012545 processing Methods 0.000 claims description 12
- 230000001902 propagating effect Effects 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000007906 compression Methods 0.000 claims description 5
- 230000006835 compression Effects 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 description 623
- 239000000306 component Substances 0.000 description 107
- 230000000670 limiting effect Effects 0.000 description 99
- 238000000576 coating method Methods 0.000 description 69
- 239000011248 coating agent Substances 0.000 description 64
- 230000002587 anti-hemolytic effect Effects 0.000 description 56
- -1 polyethylene Polymers 0.000 description 38
- 239000011148 porous material Substances 0.000 description 36
- 239000010410 layer Substances 0.000 description 33
- 239000003146 anticoagulant agent Substances 0.000 description 28
- 229940127219 anticoagulant drug Drugs 0.000 description 28
- 238000003556 assay Methods 0.000 description 22
- 239000004094 surface-active agent Substances 0.000 description 22
- 238000009826 distribution Methods 0.000 description 20
- 230000033001 locomotion Effects 0.000 description 19
- 235000014113 dietary fatty acids Nutrition 0.000 description 18
- 229930195729 fatty acid Natural products 0.000 description 18
- 239000000194 fatty acid Substances 0.000 description 18
- 206010018910 Haemolysis Diseases 0.000 description 15
- 238000000605 extraction Methods 0.000 description 15
- 229960002897 heparin Drugs 0.000 description 14
- 229920000669 heparin Polymers 0.000 description 14
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- 239000012503 blood component Substances 0.000 description 13
- 229920001223 polyethylene glycol Polymers 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 230000008588 hemolysis Effects 0.000 description 12
- 238000002386 leaching Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 11
- 238000011049 filling Methods 0.000 description 11
- 206010052428 Wound Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 229930182558 Sterol Natural products 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 229920000136 polysorbate Polymers 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 150000003432 sterols Chemical class 0.000 description 9
- 235000003702 sterols Nutrition 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 230000032258 transport Effects 0.000 description 9
- 239000002202 Polyethylene glycol Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000013022 venting Methods 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 230000000149 penetrating effect Effects 0.000 description 7
- 229920002492 poly(sulfone) Polymers 0.000 description 7
- 230000007704 transition Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000004695 Polyether sulfone Substances 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 229920002678 cellulose Polymers 0.000 description 6
- 229940049964 oleate Drugs 0.000 description 6
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 6
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 6
- 229920006393 polyether sulfone Polymers 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000005018 casein Substances 0.000 description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 5
- 235000021240 caseins Nutrition 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 229920000573 polyethylene Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 150000008163 sugars Chemical group 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229940070765 laurate Drugs 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 238000009736 wetting Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229920002301 cellulose acetate Polymers 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000007717 exclusion Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000787 lecithin Chemical class 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000005499 meniscus Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 2
- CMCBDXRRFKYBDG-UHFFFAOYSA-N 1-dodecoxydodecane Chemical compound CCCCCCCCCCCCOCCCCCCCCCCCC CMCBDXRRFKYBDG-UHFFFAOYSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- OEZPKXDBWNXBRE-UHFFFAOYSA-N 2,3-bis(2-hydroxyethoxy)propyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(OCCO)COCCO OEZPKXDBWNXBRE-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108010038807 Oligopeptides Chemical class 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000005591 charge neutralization Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- WOQQAWHSKSSAGF-WXFJLFHKSA-N decyl beta-D-maltopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](OCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 WOQQAWHSKSSAGF-WXFJLFHKSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 229940074046 glyceryl laurate Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229920000110 poly(aryl ether sulfone) Polymers 0.000 description 2
- 229920002239 polyacrylonitrile Polymers 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920001184 polypeptide Chemical class 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 108090000765 processed proteins & peptides Chemical class 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 150000003899 tartaric acid esters Chemical class 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 238000005809 transesterification reaction Methods 0.000 description 2
- 239000012780 transparent material Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- RBFSPQDASPEAID-HXUWFJFHSA-N 1,2-diheptanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCC RBFSPQDASPEAID-HXUWFJFHSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- AOWCOHYBGYRYGE-UHFFFAOYSA-N 1-[2,3-bis(2-oxopropoxy)propoxy]propan-2-one Chemical compound CC(=O)COCC(OCC(C)=O)COCC(C)=O AOWCOHYBGYRYGE-UHFFFAOYSA-N 0.000 description 1
- QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- HBXWUCXDUUJDRB-UHFFFAOYSA-N 1-octadecoxyoctadecane Chemical compound CCCCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCCCC HBXWUCXDUUJDRB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZPDQFUYPBVXUKS-YADHBBJMSA-N 1-stearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)COP(O)(=O)OC[C@H](N)C(O)=O ZPDQFUYPBVXUKS-YADHBBJMSA-N 0.000 description 1
- KHICUSAUSRBPJT-UHFFFAOYSA-N 2-(2-octadecanoyloxypropanoyloxy)propanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C(O)=O KHICUSAUSRBPJT-UHFFFAOYSA-N 0.000 description 1
- MQFYRUGXOJAUQK-UHFFFAOYSA-N 2-[2-[2-(2-octadecanoyloxyethoxy)ethoxy]ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOCCOCCOCCOC(=O)CCCCCCCCCCCCCCCCC MQFYRUGXOJAUQK-UHFFFAOYSA-N 0.000 description 1
- ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 2-dodecanoyloxyethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOC(=O)CCCCCCCCCCC ZVUNTIMPQCQCAQ-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- DUIOKRXOKLLURE-UHFFFAOYSA-N 2-octylphenol Chemical class CCCCCCCCC1=CC=CC=C1O DUIOKRXOKLLURE-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- TUBRCQBRKJXJEA-UHFFFAOYSA-N 3-[hexadecyl(dimethyl)azaniumyl]propane-1-sulfonate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O TUBRCQBRKJXJEA-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 208000032765 Device extrusion Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 241001065350 Lundia Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 229920012266 Poly(ether sulfone) PES Polymers 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- NKSOSPOXQKNIKJ-CLFAGFIQSA-N Polyoxyethylene dioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOC(=O)CCCCCCC\C=C/CCCCCCCC NKSOSPOXQKNIKJ-CLFAGFIQSA-N 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000001833 Succinylated monoglyceride Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 description 1
- KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- HFDVRLIODXPAHB-UHFFFAOYSA-N alpha-tetradecene Natural products CCCCCCCCCCCCC=C HFDVRLIODXPAHB-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000013142 basic testing Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 108700043024 cholylsarcosine Proteins 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- ZRKZFNZPJKEWPC-UHFFFAOYSA-N decylamine-N,N-dimethyl-N-oxide Chemical compound CCCCCCCCCC[N+](C)(C)[O-] ZRKZFNZPJKEWPC-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229940018602 docusate Drugs 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- QBHFVMDLPTZDOI-UHFFFAOYSA-N dodecylphosphocholine Chemical compound CCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C QBHFVMDLPTZDOI-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-M hexanoate Chemical compound CCCCCC([O-])=O FUZZWVXGSFPDMH-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Chemical class CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940008456 peg-32 oleate Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229950004354 phosphorylcholine Drugs 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 238000007842 plasma-based assay Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920005644 polyethylene terephthalate glycol copolymer Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005597 polymer membrane Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 229950006451 sorbitan laurate Drugs 0.000 description 1
- 235000011067 sorbitan monolaureate Nutrition 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 229940071209 stearoyl lactylate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019327 succinylated monoglyceride Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229940032085 sucrose monolaurate Drugs 0.000 description 1
- 229940035023 sucrose monostearate Drugs 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
- A61B5/150022—Source of blood for capillary blood or interstitial fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150053—Details for enhanced collection of blood or interstitial fluid at the sample site, e.g. by applying compression, heat, vibration, ultrasound, suction or vacuum to tissue; for reduction of pain or discomfort; Skin piercing elements, e.g. blades, needles, lancets or canulas, with adjustable piercing speed
- A61B5/150061—Means for enhancing collection
- A61B5/150099—Means for enhancing collection by negative pressure, other than vacuum extraction into a syringe by pulling on the piston rod or into pre-evacuated tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150343—Collection vessels for collecting blood samples from the skin surface, e.g. test tubes, cuvettes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150358—Strips for collecting blood, e.g. absorbent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150389—Hollow piercing elements, e.g. canulas, needles, for piercing the skin
- A61B5/150396—Specific tip design, e.g. for improved penetration characteristics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150374—Details of piercing elements or protective means for preventing accidental injuries by such piercing elements
- A61B5/150381—Design of piercing elements
- A61B5/150503—Single-ended needles
- A61B5/150511—Details of construction of shaft
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/38—Polyalkenylalcohols; Polyalkenylesters; Polyalkenylethers; Polyalkenylaldehydes; Polyalkenylketones; Polyalkenylacetals; Polyalkenylketals
- B01D71/381—Polyvinylalcohol
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
- B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150206—Construction or design features not otherwise provided for; manufacturing or production; packages; sterilisation of piercing element, piercing device or sampling device
- A61B5/150305—Packages specially adapted for piercing devices or blood sampling devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/02—Details relating to pores or porosity of the membranes
- B01D2325/022—Asymmetric membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/76—Macromolecular material not specifically provided for in a single one of groups B01D71/08 - B01D71/74
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0684—Venting, avoiding backpressure, avoid gas bubbles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0816—Cards, e.g. flat sample carriers usually with flow in two horizontal directions
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0403—Moving fluids with specific forces or mechanical means specific forces
- B01L2400/0406—Moving fluids with specific forces or mechanical means specific forces capillary forces
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2400/00—Moving or stopping fluids
- B01L2400/04—Moving fluids with specific forces or mechanical means
- B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
- B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
Definitions
- a blood sample for use in laboratory testing is often obtained by way of venipuncture, which typically involves inserting a hypodermic needle into a vein on the subject. Blood extracted by the hypodermic needle may be drawn directly into a syringe or into one or more sealed vials for subsequent processing. When a venipuncture may be difficult or impractical such as on a newborn infant, a non-venous puncture such as a heel stick or other alternate site puncture may be used to extract a blood sample for testing. After the blood sample is collected, the extracted sample is typically packaged and transferred to a processing center for analysis.
- a device for use with a formed component liquid sample, the device comprising at least one sample inlet for receiving said sample; at least a first outlet for ouiputting only a liquid portion of the formed component liquid sample; at least a second outlet for ouiputting the formed component liquid sample at least a first material mixed therein.
- the body may a first pathway fluidically couples the sample inlet with the first outlet.
- a second pathway fluidically couples the sample inlet with the second outlet.
- a separation material along the fsrst pathway configured to remove said formed component from the sample prior to outputting at the first outlet.
- the separation material and a distributor are configured to have an interface that provides a multi-mode sample propagation pattern wherein at least a first portion is propagating laterally within the separator and a second portion is propagating through the channels of the distributor over the separator.
- the inlet directs the sample to primarily contact a planar portion of separator surface, and not a lateral edge of the separator.
- the amount of time for sample to fill the first pathway and reach the first outlet is substantially equal to the time for sample to fill the second pathway and reach the second outlet.
- the first pathway comprises a portion configured in a distributed pattern of channels over the filtration material to preferentially direct the sample over the surface of the separation material in a pre-determined configuration.
- at least a portion of the separation material is coupled to a vent which contacts the membrane in a manner that the vent is only accessible fluidically by passing through the separation material.
- containers have interiors under vacuum pressure that draw sample therein.
- the separation material is held in the device under compression.
- the separation material comprises an asymmetric porous membrane.
- the separation material is a mesh.
- the separation material comprises polyethylene (coated by ethylene vinyl alcohol copolymer).
- the separation material comprises a polyethersulfone.
- the separation material comprises an asymmetric
- the separation material comprises
- the separation material comprises an asymmetric polyaiylethersulfone.
- at least a portion of the separation material comprises a polysulfone.
- the separation material comprises an asymmetric polysulfone.
- the separation material comprises a cellulose or cellulose derivative material.
- the separation material comprises polypropylene (PP).
- the separation material comprises polymethylmethacrylate (PMMA).
- the separation material comprises a polymer membrane wherein filtrate exit surface of the membrane comprises a relatively open pore structure and the opposite surface comprises a more open pore structure and wherein the supporting structure comprises asymmetry through at least 50% of the supporting structure but no more than 95% of the supporting structure, the membrane
- the flow rate of the material, unassisted is between 1 cm/min/psi and 4.3 2 cm/min/psi.
- a device for collecting a bodily fluid sample from a subject comprising: at least two sample collection pathways configured to draw the bodily fluid sample into the device from a single end of the device in contact with the subject, thereby separating the fluid sample into two separate samples; a second portion comprising a plurality of sample containers for receiving the bodily fluid sample collected in the sample collection pathways, the sample containers operably engagable to be in fluid
- the device includes a separation material along one of the sample collection pathways, the material configured to remove formed components from the sample when outputting to at least one of the sample containers.
- a device for collecting a bodily fluid sample comprising: a first portion comprising at least one fluid collection location leading to at least two sample collection pathways configured to draw the fluid sample therein via a first type of motive force; a second portion comprising a plurality of sample containers for receiving the bodily fluid sample collected in the sample collection pathways, the sample containers operably engagable to be in fluid communication with the sample collection pathways, whereupon when fluid communication is established, the containers provide a second motive force different from the first motive force to move a majority of the bodily fluid sample from the pathways into the containers; wherein at least one of the sample collection pathways comprises a fill indicator to indicate when a minimum fill level has been reached and that at least one of the sample containers can be engaged to be in fluid communication with at least one of the sample collection pathways.
- the device includes a separation material along one of the sample collection pathways, the material configured to remove formed components from the sample when outputting to at least one of the sample containers.
- a device for collecting a bodily fluid sample comprising a first portion comprising at least two sample collection channels configured to draw the fluid sample into the sample collection channels via a first type of motive force, wherein one of the sample collection channels has an interior coating designed to mix with the fluid sample and another of the sample collection channels has another interior coating chemically different from said interior coating; a second portion comprising a plurality of sample containers for receiving the bodily fluid sample collected in the sample collection channels, the sample containers operably engagable to be in fluid communication with the collection channels, whereupon w r hen fluid communication is established, the containers provide a second motive force different from the first motive force to move a majority of the bodily fluid sample from the channels into the containers; wherein containers are arranged such that mixing of the fluid sample between the containers does not occur.
- the device includes a separator along one of the sample collection channels, the separator configured to remove formed component from the sample when outputting to at least one of the sample containers.
- a device for collecting a bodily fluid sample comprising: a first portion comprising a plurality of sample collection channels, wherein at least two of the channels are configured to simultaneously draw the fluid sample into each of the at least two sample collect ion channels via a first type of motiv e force; a second portion comprising a plurality of sample containers for receiving the bodily fluid sample collected in the sample collection channels, wherein the sample containers have a first condition where the sample containers are not in fluid communication with the sample collection channels, and a second condition where the sample containers are operably engagable to be in fluid communication with the collection channels, whereupon w r hen fluid communication is established, the containers provide a second motive force different from the first motive force to move bodily fluid sample from the channels into the containers.
- the device includes a separator along one of the sample collection channels, the separator configured to remove fonned component from the sample when outputting to at least one of the sample containers.
- a sample collection device comprising: (a) a collection channel comprising a first opening and a second opening, and being configured to draw a bodily fluid sample via capillary action from the first opening towards the second opening; and (b) a sample container for receiving the bodily fluid sample, the container being engagable with the collection channel, having an interior with a vacuum therein, and having a cap configured to receive a channel; wherein the second opening is defined by a portion the collection channel configured to penetrate the cap of the sample container, and to provide a fluid flow path between the collection channel and the sample container, and the sample container has an interior volume no greater than ten times larger than the interior volume of the collection channel.
- the device comprises a separator along one of the sample collection channel, the separator configured to remove formed component from the sample prior to and when outputting to the sample container.
- a sample collection device comprising: (a) a collection channel comprising a fsrst opening and a second opening, and being configured to draw a bodily fluid sample via capillary action from the first opening towards the second opening; (b) a sample container for receiving the bodily fluid sample, the container being engagable with the collection channel, having an interior with a vacuum therein, and having a cap configured to receive a channel; and (c) an adaptor channel configured to provide a fluid flow path between the collection channel and the sample container, having a first opening and a second opening, the first opening being configured to contact the second opening of the collection channel, the second opening being configured to penetrate the cap of the sample container.
- the device comprises a separator along one of the sample collection channel, the separator configured to remove formed component from the sample prior
- a sample collection device comprising: (a) a body, containing a collection channel , the collection channel comprising a first opemng and a second opening, and being configured to draw a bodily fluid via capillary action from the first opening towards the second opening; fb) a base, containing a sample container for receiving the bodily fluid sample, the sample container being engagable with the collection channel, having an interior with a vacuum therein, and having a cap configured to receive a channel; and (c) a support, wherein, the body and the base are connected to opposite ends of the support, and are configured to be movable relative to each other, such that sample collection device is configured to have an extended state and a compressed state, wherein at feast a portion of the base is closer to the body in the extended state of the device than in the compressed state, the second opening of the collection channel is configured to penetrate the cap of the sample container, in the extended state of the device, the second opening of the collection channel is
- a sample collection device comprising: (a) a body, containing a collection channel , the collection channel comprising a first opening and a second opening, and being configured to draw a bodily fluid via capillary action from the first opening towards the second opemng; (b) a base, containing a sample container for receiving the bodily fluid sample, the sample container being engagable with the collection channel, having an interior with a vacuu therein and having a cap configured to receive a channel; (c) a support, and (d) an adaptor channel, having a first opening and a second opening, the first opening being configured to contact the second opening of the collection channel and me second opening being configured to penetrate the cap of the sample container, wherein, the body and the base are connected to opposite ends of the support, and are configured to be movable relative to each other, such that sample collection device is configured to have an extended state and a compressed state, wherein at least a portion of the base is closer to the
- a device for collecting a fluid sample from a subject comprising: (a) a body containing a collection channel, the collection channel comprising a first opening and a second opening, and being configured to draw a bodily fluid via capillary action from the first opening towards the second opening; (b) a base, engagable with the body, wherein the base supports a sample container, the container being engagable with the collection channel, having an interior with a vacuum therein, and having a cap configured to receive a channel; wherein the second opening of the collection channel is configured to penetrate the cap of the sample container, and to provide a fluid flow path between the collection channel and the sample container.
- the device comprises a separator along one of the sample collection channel, the separator configured to remove formed component from the sample prior to and when outputting to the sample container.
- a device for collecting a fluid sample from a subject comprising: (a) a body containing a collection channel, the collection channel comprising a first opening and a second opening, and being configured to draw a bodily fluid via capillary action from the first opening towards the second opening; (b) a base, engagable with the body, wherein the base supports a sample container, the sample container being engagable with the collection channel, having an interior with a vacuum therein and having a cap configured to receive a channel: and (c) an adaptor channel, having a first opening and a second opening, the fsrst opening being configured to contact the second opening of the collection channel, and the second opening being configured to penetrate the cap of the sample container.
- the device comprises a separator along one of the sample collection channel, the separator configured to remove formed component from the sample prior to and when outputting to the sample container,
- the body may comprise of two collection channels.
- the interior of the collection channel(s) are coated with an anticoagulant.
- the body comprises a first collection channel and a second collection channel, and the interior of the first collection channel is coated with a different aniicoaguiant than the interior of the second collection channel
- the first anticoagulant is ethylenediaminetetraacetic acid (EDTA) and the second anticoagulant is different from EDTA.
- the first anticoagulant is citrate and the second anticoagulant is different from citrate.
- the first anticoagulant is heparin and the second anticoagulant is different from heparin.
- one anticoagulant is heparin and the second anticoagulant is EDTA.
- one anticoagulant is heparin and the second anticoagulant is citrate.
- one anticoagulant is citrate and the second anticoagulant is EDTA.
- the body is formed from an optically transmissive material.
- the device includes the same number of sample containers as collection channels.
- the device includes the same number of adaptor channels as collection channels.
- the base contains an optical indicator that provides a visual indication of whether the sample has reached the sample container in the base.
- the base is a window that allows a user to see the container in the base.
- the support comprises a spring, and spring exerts a force so that the device is at the extended state when the device is at its natural state.
- the second opening of the collection channel or the adaptor channel is capped by a sleeve, wherein said sleeve does not prevent movement of bodily fluid via capillary action from the first opening towards the second opening.
- each collection channel can hold a volume of no greater than 500 uL.
- each collection channel can hold a volume of no greater than 200 uL.
- each collection channel can hold a volume of no greater than 100 uL.
- each collection channel can hold a volume of no greater than 70 uL.
- each collection channel can hold a volume of no greater than 500 uL.
- each collection channel can hold a volume of no greater than 30 uL.
- the internal circumferential perimeter of a cross-section of each collection channel is no greater than 16 mm.
- the internal circumferential perimeter of a cross- section of each collection channel is no greater than 8 mm.
- the internal circumferential perimeter of a cross- section of each collection channel is no greater than 4 mm.
- the internal circumferential perimeter of a cross-section of each collection channel is no greater than 16 mm.
- the internal circumferential perimeter of a cross- section of each collection channel is no greater than 8 mm.
- the device comprises a first and a second collection channel, and the opening of ihe first channel is adjaceni io an opening of said second channel, and the openings are configured to draw blood simultaneously from a single drop of blood.
- the opening of the first channel and the opening of the second channel have a center -to-center spacing of less than or equal to about 5 mm.
- each sample container has an interior volume no greater than twenty times larger than the interior volume of the collection channel with which it is engagable.
- each sample container has an interior volume no greater than ten times larger than the interior volume of the collection channel with which it is engagable.
- each sample container has an interior volume no greater than five times larger than the interior volume of the collection channel with which it is engagable.
- each sample container has an interior volume no greater than two times larger than the interior volume of the collection channel with which it is engagable.
- establishment of fiuidic communication between the collection channel and the sample container results in transfer of at feast 90% of the bodily fluid sample in the collection channel into the sample container.
- establishment of fiuidic communication between of the collection channel and the sample container results in transfer of at least 98% of the bodily fluid sample in the coll ection channel into the sample container.
- establishment of fiuidic communication between the collection channel and the sample container results in transfer of the bodily fluid sample into the sample container and in no more than ten uL of bodily fluid sample remaining in the collection channel.
- establishment of fiuidic communication between the collection channel and the sample container results in transfer of the bodily fluid sample into the sample container and in no more than five uL of bodily fluid sample remaining in the collection channel.
- the channels have a cross-sectional shape characterized by a greater width than height.
- the channels are distributed in a pattern where at least some of the channels intersect other channels to form a grid pattern.
- the sample inlet introduces the sample over the manifold.
- the sample inlet introduces the sample along at least an edge or lateral side portion of the manifold.
- the sample inlet -introduces the sample over the manifold and at least a lateral side portion of the manifold.
- a method comprising contacting one end of a sample collection device to a bodily fluid sample to split the sample into at least two portions by drawing the sample into at least two collection channels of the sample collection device by way of a fsrst type of motive force; establishing fluid communication between the sample collection channels and the sample containers after a desired amount of sample fluid has been confirmed to be in at leas t one of the collec tion channels, whereupon the containers provide a second motive force different from the first motive force to move each of the portions of bodily fluid sample into their respective containers.
- a method comprising metering a minimum amount of sample into at least two channels by using a sample collection device with at least two of the sample collection channels configured to simultaneously draw the fluid sample into each of the at least two sample collection channels via a first type of motive force; after a desired amount of sample fluid has been confirmed to be in the collection channels, fluid communication is established between the sample collection channels and the sample containers, whereupon the containers provide a second motive force different from the first motive force use to collect the samples to move bodily fluid sample from the channels into the containers.
- a method of collecting a bodily fluid sample comprising (a) contacting a bodily fluid sample with a device comprising a collection channel, the collection channel comprising a first opening and a second opening, and being configured to draw a bodily fluid via capillar action from the first opening towards the second opening, such that the bodily fluid sample fills the collection channel from the first opening through the second opening; (b) establishing a fluid flow path between the collection channel and the interior of a sample container , said sample container having an interior volume no greater than ten times larger than the interior volume of the collection channel and having a vacuum prior to establishment of the fluid flow path between the collection channel and the interior of the sample container, such that establishment of the fluid flow path between the collection channel and the interior of the sample container generates a negative pressure at the second opening of the collection channel, and the fluidic sample is transferred from the collection channel to the interior of the sample container,
- a method of collecting a bodily fluid sample comprising (a) contacting a bodily fluid sample with any collection device as described herein, such that the bodily fluid sample fills the collection channel from the first opening through the second opening of at least one of the collection channel(s) in the device; and (b) establishing a fluid flow path between the collection channel and the interior of the sample container , such that establishing a fluid flow path between the collection channel and the interior of the sample container generates a negative pressure at the second opening of the collection channel, and the fluidic sample is transferred from the collection channel to the interior of the sample container.
- the collection channel and the interior of the sample container are not brought into fluid communication until the bodily fluid reaches the second opening of the collection channel.
- the device comprises two collection channels, and the collection channels and the interior of the sample containers are not brought into fluidic communication until the bodily fluid reaches the second opening of both collection channels.
- the second opening of the collection channel in the device is configured to penetrate the cap of the sample container, and wherein a fluidic flow path between the second opening of the collection channel and the sample container is established by providing relative movement between the second opening of the collection channel and the sample container, such that the second opening of the collection channel penetrates the cap of the sample container.
- the device comprises an adaptor channel for each collection channel in the device, the adaptor channel having a first opening and a second opening, the first opening being configured to contact the second opening of the collection channel, and the second opening being configured to penetrate the cap of the sample container, and wherein a fluidic flow path between the collection channel and the sample container is established by providing relative movement between two or more of: (a) the second opening of the collection channel, (b) the adaptor channel, and (c) the sample container, such that the second opening of the adaptor channel penetrates the cap of the sample container.
- a method for collecting a bodily fluid sample from a subject comprising: (a) bringing a device comprising a first channel and a second channel into fluidic communication with a bodily fluid from the subject, each channel having an input opening configured for fluidic communication with said bodily fluid, each channel ha v ing an output opening downstream of the input opening of each channel, and each channel being configured to draw a bodily fluid via capillary action from the input opening towards the output opening; (b) bringing, through the output opening of each of the first channel and the second channel, said first channel and said second channel into fluidtc communication with a first container and a second container, respectively: and (c) directing said bodily fluid within each of said first channel and second channel to each of said first container and second container with the aid of: (i) negative pressure relative to ambient pressure in said first container or said second container, wherein said negative pressure is sufficient to effect flow of said bodily fluid through said first channel or said second channel into its corresponding container, or (i
- a method of manufacturing a sample collection device comprising forming one portion of a sample collection device having at least two channels configured to simultaneously draw the fluid sample into each of the at least two sample collection channels via a first type of motive force; forming sample containers, whereupon the containers are configured to be coupled to the sample collection device to the provide a second motive force different from the first motive force use to collect the samples to move bodily fluid sample from the channels into the containers,
- computer executable instructions are provided for performing a method comprising: forming one portion of a sample collection device having at least two channels configured to simultaneously draw the fluid sample into each of the at least two sample collection channels v ia a first type of moti ve force.
- computer executable instructions for performing a method comprising: forming sample containers, whereupon the containers are configured to be coupled to the sample collection device to provide a second motive force different from the first motive force use to collect the samples to move bodily fluid sample from the channels into the containers.
- a device for collecting a bodily fluid sample from a subject comprising: means for drawing the bodily fluid sample into the device from a single end of the device in contact with the subject, thereby separating the fluid sample into two separate samples; means for transferring the fluid sample into a plurality of sample containers, wherein the containers provide a motive force to move a majority of the two separate samples from the pathways into the containers.
- the desired range of channel surface area relative to the surface area of the separator on that side of the separator is in the range of about 35% to 70%.
- the desired range of channel surface area relative to the surface area of the separator on that side of the separator is in the range of about 40% to 70%.
- the desired range of channel surface area relati v e to the surface area of the separator on that side of the separator is in the range of about 50% to 60%.
- a method comprising collecting a bodily fluid sample into a collection channel, the collection channel comprising a first opening and a. second opening, and being configured to draw the bodily fluid via capillary action from the first opening towards the second opening; and using a separator along the sample collection channel to remove formed component from the sample prior to and when outputtmg to the sample container.
- a method comprising collecting a bodily fluid sample into device having a first collection channel and a second collection channel, the collection channel comprising a first opening and a second opening, and being configured to draw the bodily fluid via capillary action from the first opening towards the second opening; using a separator along the first sample collection channel to remove formed component from the sample prior to and when outputting to the sample container; wherein when the bodily fluid sample is blood, the device outputs both blood and plasma, each from separate outlets, from the one sample collected into the device.
- separation materials on a bodily fluid to allow for plasma-based assays.
- the desired list of assays includes not only- large molecules such as proteins and lipids, but also smaller metabolites such as those that are part of the complete metabolic panel and examples include but are not limited to glucose, calcium, magnesium, etc.... Since the plasma separation materials were not primarily designed for these assay s but for use in select types of test- strip based assays, the hemolysis-preventing agent used in these materials can interfere with other assay chemistries.
- the separation material may have a coating of a protective material such as but not limited to an anti- hemolytic material like single and/or double alkyi chain N-oxides of tertiary amines (NTA).
- a protective material such as but not limited to an anti- hemolytic material like single and/or double alkyi chain N-oxides of tertiary amines (NTA).
- separation material coating can constitute a combination of an anti-hemolytie (such as surfactant, protein, sugar, or a combination of these), alongside an anti -coagulant (such as EDTA and its derivatives or Heparin).
- NTA generally does not interfere with several large molecule assays.
- NTA is a chelating agent that strongly binds to di-vending cations such as calcium and magnesium ions.
- the coating in some embodiments, can be one or more of the following: anti-coagulant, anti- hemolytic, and molecules for surface coverage. Any of these may interfere with assays.
- Some embodiments disclosed herein are directed toward multi-region separation material structures with capture region(s) and pass-through region(s) with different surface treatments.
- these separation materials may be asymmetric or non- asymmetric separation materials.
- Some embodiments have bi-iayer, tri-layer, or other multi-layer configurations.
- Some embodiments may be continuously asymmetric with the asymmetric region extending from an upper surface of the material to a lower surface of the material.
- some embodiment may have only one or more portions of the material that are asymmetric while one or more other regions are isotropic in terms of pore size.
- Some embodiments may have an asymmetric material that is then bonded to at least another material that is isotropic to create a desired pore size distribution profile.
- the asymmetric region may have the larger pore sizes and be coated with anti-hemolytic material.
- Some embodiments can have separation materials with gradation in coating material thickness and/or coverage to position material such as the hemolysis-preventing material in areas where the material is likely to be in contact with formed components captured by the separation material.
- separation materials may be washed in a manner the preferentially remo ves the anti-hemolytic material from at least one region of the separation material, such as the inner portions of the separation material, but not the exterior portions that are more likely to come into direct contact with formed components of the bodily fluid.
- Other variations or alternative coating schemes to create separation materials or filter structures with areas of leaching and non-leaching materials are not excluded.
- separation materials can also be coated with at least two different materials that may both leach into the bodily fluid, but at least one of these materials that may leach into the fluid does not impact assay measurements and can be used to overcoat the other material and thus decrease the surface area exposure of the other material to the bodily fluid.
- the separation material comprises an asymmetric porous membrane.
- the separation material is a mesh.
- the separation material comprises polyethylene (coated by ethylene vinyl alcohol copolymer).
- at least a portion of the separation material comprises a polyethersulfone.
- at least a portion of the separation material comprises an asymmetric polyethersulfone.
- at least a portion of the separation material comprises polyarylethersulfone.
- at least a portion of the separation material comprises an asymmetric polyarylethersulfone.
- at least a portion of the separation material comprises a polysulfone.
- the separation material comprises an asymmetric polysulfone.
- the separation material comprises a cellulose or cellulose derivative material.
- the separation material comprises polypropylene (PP).
- the separation material comprises polymethylmethacrylate (PMMA).
- a bodily fluid separation material comprising a formed component capture region having an anti-hemolytic surface layer; a bodily fluid pass-through region comprising pass-through openings sized so that formed components do not enter the bodily fluid pass-through region and a reduced amount of fluid leaching material relative to than the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region.
- a bodily fluid separation material comprising an anti-hemolytic, formed component capture region; a bodily fluid pass-through region comprising pass-through openings sized so that formed components do not enter the bodily fluid pass-through region and having a reduced amount of anti-hemolytic material relative to the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region.
- a bodily fluid separation material comprising a first filter region of the separation material having an anti-hemolytic coating and pore spacing sized to constrain formed blood componenis therein; a second filter region of the separation material having pore spacing smaller than pore spacing of the fsrst filter region with pores sized so that formed components do not enter the second filter region and configured to have an amount of anti-hemoly tic coating less than that of the first region.
- a bodily fluid separation material comprising a percolating network configured to capture formed blood components: a first region of the percolating network with an anti-hemolytic coating on structures in the region, said network with openings sized and spaced to allow formed blood components to enter the first region but constraining blood components therein from passing completely through the first region; a second region of the percolating network with a reduced anti-hemolytic coating on structures sized and spaced to prevent formed blood components from entering the second region; wherein bodily fluid passes through the first region prior to reaching the second region.
- a separation material may be a mesh.
- at least a portion of the separation material comprises a polyethersulfone.
- the separation material comprises an asymmetric
- the separation material comprises
- the separation material comprises an asymmetric polyaiylethersulfone.
- at least a portion of the separation material comprises a polysuifone.
- the separation material comprises an asymmetric polysulfone.
- the anti-hemolytic material on the separation material comprises single and/or double alkyl chain N-oxides of tertiary amines (NT A).
- the first region comprises a first separation material layer and the second region comprises a second separation material layer.
- the separation material comprises a first separation material coupled to a second separation material.
- the separation material comprises at least two separate separation materials.
- the first region is in fluid communication with the second region.
- the first region is spaced apart from the second region.
- a method of forming a bodily fluid separation material comprising coating the separation material with an anti-hemolytic coating on a first region and a second region of the separation material; reducing anti-hemolytic effect of the second region of th e separation material rel ative to the first region, wherein when the separation material is in operation, bodily fluid passes through the first region prior to reaching the second region.
- a method of forming a bodily fluid separation material comprising coating at least a first region of the separation material with an anti-hemolytic coating; not coating at least second region of the separation material with the anti- hemolytic coating.
- reducing the anti-hemolytic effect may comprise washing off at least a portion of the anti-hemolytic coating on the second region.
- washing off comprises directing solvent through the separation material.
- washing off comprises soaking only a portion of the separation material in a solvent.
- the anti-hemolytic effect comprises adding another coating of a different material over the ants- hemolytic coating on the second region.
- reducing the anti-hemolytic effect comprises treating the separation material to bring its electrical charge state to a neutral state and thus reduce the attraction of ions that increase the anti-hemolytic effect.
- a device for collecting a sample from a subject and outputtmg a filtrate from the sample.
- a device for collecting a sample from a subject and forming a filtrate from at least a portion of the sample.
- a method is provided of using a device for collecting a sample from a subject and outputting a filtrate from the sample.
- a method is provided of processing a formed component separation membrane.
- a method is provided of processing a formed component separation material.
- a method comprising using a separation material coupled to a housing to separate a formed component portion of the sample from a liquid portion of the sample.
- a method comprising at least one technical feature from any of the prior disclosed features.
- a method is provided comprising at least any two technical features from any of the prior disclosed features.
- a device comprising at least one technical feature from any of the prior disclosed features.
- device comprising at least any two technical features from any of the prior disclosed features.
- a system comprising at least one technical feature from any of the prior disclosed features.
- a system comprising at least any two technical features from any of the prior disclosed feaiures.
- Figure 1 shows a schematic view of a device according to one embodiment described herein.
- Figures 2. to 4 show various views of a device according to one embodiment described herein.
- Figures 5A-5B show top-down plan views of devices according to embodiments described herein.
- Figures 6-7 show various views of a device according to one embodiment described herein.
- Figures 8-9 show various views of a device according to one embodiment described herein.
- Figures 10-1 1 show various views of a device having at least two sample pathways according to one embodiment described herein.
- Figures 12-13 show various views of a device according to one embodiment described herein.
- Figures 14- 19 show cross-sectional views of various configurations for sample inlet openings and channels according to embodiments herein.
- Figures 20-21 show views of various configurations for sample inlets according to embodiments herein.
- Figures 22-28 show various patterns for sample distribution pathways according to embodiments herein.
- Figures 29-30 show various views of a device according to one embodiment described herein.
- Figures 31 -32 show various views of a device according to one embodiment described herein.
- Figures 33-34 sho various views of a device according to one embodiment described herein.
- Figure 35 shows various views of geometric configuration for the separator according to embodiments described herein.
- Figures 36-38 show one non- limiting example of sample inlet flow over the separator according to embodiments described herein.
- Figures 39-42 show one non-limiting example of sample outlet flow from the separator according to embodiments described herein.
- Figures 43-44 show side cross-sectional views of embodiments described herein.
- Figures 45-46 show top down plan v ews of vents according to embodiments described herein.
- Figures 47A-48B show various views of sample wetting of a separator according to embodiments described herein.
- Figures 49-51 show top down plan views of various distribution channel patterns over the separator according to embodiments described herein.
- Figure 52 shows cross-sectional views of various channel patterns and shapes over and under the separator according to embodiments described herein.
- Figures 53-55 show non-limiting examples of various aspect ratios of the separator according to embodiments described herein.
- Figure 56 shows a side cross-sectional view of one non-limiting example of an exit pathway according to embodiments described herein.
- Figures 57 to 59 sho w views of non-limiting examples of de v ices having at least two sample pathways according to embodiments described herein.
- Figure 60 shows yet another configuration of a device according to embodiments herein.
- Figure 61 shows one non-limiting example of a cartridge having a sample collector and sample separator according to embodiment herein.
- Figures 62 to 77 show still further embodiments as described herein.
- Figure 78 shows a side, cross-sectional view of a separation material according to one embodiment described herein.
- Figure 79 shows an exploded side, cross- sectional view of separation materials according to one embodiment described herein.
- Figure 80 is schematic of a multi-layer separation material according to one embodiment described herein.
- Figures 81 and 82 illustrate methods according to embodiments described herein,
- Figure 83 shows one mode of operation according to at least one embodiment described herein.
- the terms “substantial” means more than a minimal or insignificant amount; and “substantially” means more than a minimally or insignificantly.
- the phrase “substantially different”, as used herein denotes a sufficiently high degree of difference between two numeric values such that one of skill in the art would consider the difference between the two values to be of statistical significance within the context of the characteristic measured by said values.
- the difference between two values that are substantially different from each other is typically greater than about 10%, and may be greater than about 20%, preferably greater than about 30%, preferably greater than about 40%, preferably greater than about 50% as a function of the reference value or comparator value.
- a sample may be but is not limited to a blood sample, or a portion of a blood sample, may be of any suitable size or volume, and is preferably of small size or volume.
- measurements may be made using a small volume blood sample, or no more than a small volume portion of a blood sample, where a small volume comprises no more than about 5 mL: or comprises no more than about 3 mL; or comprises no more than about 2 mL; or comprises no more than about 1 mL; or comprises no more than about 500 ⁇ ; or comprises no more than about 250 LIL; or comprises no more than about 100 , uL; or comprises no more than about 75 ,uL; or comprises no more than about 50 s uL; or comprises no more than about 35 ⁇ .,; or comprises no more than about 25 ,uL; or comprises no more than about 20 iiL; or comprises no more than about 15 ⁇ ,; or comprises no
- the term "point of service location” may include locations where a subject may receive a service (e.g. testing, monitoring, treatment diagnosis, guidance, sample collection, ID verification, medical services, non-medical se dees, etc.), and may include, without limitation, a subject's home, a subject's business, the location of a healthcare provider (e.g., doctor), hospitals, emergency rooms, operating rooms, clinics, health care professionals' offices, laboratories, retailers [e.g. pharmacies (e.g., retail pharmacy, clinical pharmacy, hospital pharmacy), drugstores, supermarkets, grocers, etc.], transportation vehicles (e.g.
- the term "separator” may include a mesh, a filter, a membrane, a porous membrane, an asymmetric porous membrane, a semipermeable hollow fiber membrane, a percolating network structure, a material that can be used for size-exclusion of objects greater than a certain dimension, or other filtering material.
- Materials useful for the preparation of the separating material may be selected from the group comprising polyethylene (coated by ethylene vinyl alcohol copolymer), polyacrylates, polystyrene, polyethylene oxide, cellulose, cellulose derivatives, polyethersulfone (PES), polypropylene (PP), polysulfone (PSU),
- PMMA polymetlxyimethacyiate
- PC polycarbonate
- PAN polyacrylonitrile
- PA polyamide
- PTFE polytetrafluorethylene
- CA cellulose acetate
- regenerated cellulose and blends or copolymers of the foregoing, or blends or copolymers with hydrophiiizing polymers, including with polyvinylpyrollido e (PVP) or polyethyleneoxide (PEG).
- Suppliers of such materials and/or membranes include but are not limited to BASF, Advanced Microdevices P. Ltd., International Point of Care Inc., Gambro Lundia AB, Asahi Kasei Kuraray Medical Co., Ltd., GE Healthcare (Whatman division), or the like.
- sample and “biological sample” refer to a blood, urine, sputum, tears, material(s) from a nasal swab, throat swab, cheek swab, or other bodily fluid, excretion, secretion, or tissue obtained from a subject. These terms are inclusive of an entire sample and of a portion of a sample.
- reference to a fluid sample includes reference to a sample and a biological sample.
- Such samples may include fluids into which material has been deposited, where such material may be obtained from a nasal swab, throat swab, cheek swab, or other sample which may include solid or semi-solid material, whether along with or without natural fluids.
- Such fluids and samples comprise fluid samples and sample solutions.
- formed component may include solid, semi-solid, or cellular structures such as but not limited to red blood cells, white blood cells, platelet, or other components that may be found in a sample, a biological sample, bodily fluid, or natural fluid.
- fill and “filled” and their grammatical equivalents, e.g., as used in phrases such as "a vessel may be filled with a sample solution” refer to the transfer of any amount, including partial filling and complete filling. These terms as used herein do not require that such filling completely fill a container, but include any lesser amount of filling as well.
- the devices herein can be configured for use with sample applied to the device, sample drawn into the device by capillary force, sample delivered into the device by way of venipunture, sample delivered into the device by way of arterial puncture, nasal swab, tear collection, collection from any open wound, biopsy, or other sample delivery or acquisition technique and is not limited to any specific example described herein.
- Figure 1 shows a side cross-sectional view of a device 10 having a formed component separator 20 positioned along a pathway as indicated by arrow 30.
- the device 10 has at least one sample inlet 40 for receiving a liquid sample that has the formed components there and at least a first outlet 50 for outputting only a liquid portion of the formed component liquid sample.
- the pathway 30 fluidically couples the sample inlet with the fsrst outlet.
- Figure 1 also shows that sample such as but not limited to blood flows from the inlet 40 and into and/or over the formed component separator 20.
- blood enters the formed component separator 20, where blood cells are trapped based on the principle of size exclusion.
- the formed component separator 20, in one embodiment, may have a plurality of pores wherein those on one surface are significantly smaller than those on another surface of the separator 20. In this manner, the cells in the blood can enter the separator 20 through the larger pores but cannot pass completely through the separator due to the much smaller pores on the output side of the separator 2.0.
- the liquid portion of the sample such as but not limited to plasma is pulled away from the back of the separator 20 via a combination of capillary action and/or applied pressure differential.
- Plasma flows away from the separator 20 as indicated by arrow 30.
- the walls within the device 10 may be coated with materia] such as but not limited to anti-coagulant for mixing with the sample during filling.
- the device 100 has an inlet 102 that is open towards a top surface of the device 100.
- the inlet 102 is connected by a channel 104 to a distributor 1 10 that preferentially spreads the sample over the separator 20,
- the liquid portion of the sample is outputted to ihe collector 120 which may be directed to an external channel 130 such as a needle or adapter channel.
- the distributor 1 10 is not restricted to any particular structure or material and may be a plurality of capillary channels or tubes that distribute the sample over the membrane. In some embodiments, it may be a hydrophiiic coating that may be a continuous coating or a patterned coating to draw- sample to flow over the membrane.
- FIG. 3 a cross-sectional view of one portion of the device 100 (as indicated by arrows 3-3 in Figure 2) shows some of the details regarding this embodiment of ihe disiributor 1 10 that preferentially spreads the sample over the separator 20, and the collector 120 which draws liquid away from the separator 20. Sample will flo across the separator 20 as indicated by arrow 122.
- the lead-in channel 130 wicks blood in from the inlet 102 and transports it into the distribution channel network of distributor 1 10 via capillary action.
- the distribution channel network comprises a network of capillaries on the blood side of the separator 20, This distributor 1 10 pulls sample away from the lead-in channel and distributes it evenly over the membrane.
- the separator 20 separates plasma from whole blood via a two-step process.
- One process uses a passive mechanism: gravity and capillary force gradient.
- a second process uses an active mechanism: application of a pressure differential.
- Capillaries of collector 120 also route the liquid portion of the sample into the extraction port when the pressure differential is applied. Sample flow through the device 100 is indicated by arrow 140.
- Figure 5A shows a sample separation device 150 that has an aspect ratio that provides for fewer numbers of channels but increases the length of each of the channels.
- the length of the membrane al ong a longitudinal axis of the device, rel ative to the width may be in a range of about 3: 1 to about 5: 1.
- Figure 5B shows another embodiment of a separation device 160 that has a different aspect ratio which an increased number of capillary channels, but reduced length for each.
- the length of the membrane along a longitudinal axis of the device, relative to the width may be in a range of about 1 : 1 to about 1 :3.
- the cross-sectional size of channels over separator 20 and those beneath the separator 20 can also be different.
- the channels in the collector 120 that are beneath the separator 20 are at least 2x smaller in cross-sectional area than those over the channel.
- the channels in the collector 12.0 that are beneath the separator 20 are at least 5x smaller in cross-sectional area than those over the channel.
- the channels in me collecior 120 that are beneath the separator 20 are at least lOx smaller in cross-sectional area than those over the channel. The decreased size of the channels will increase the capillary pressure and thus preferentially direct liquid portions of the sample towards the output of the device.
- FIG. 6 shows a top-down view of a bottom portion of the separation device 170 is shown with a vent 172, a vent inlet channel 173, and a collector 176 is shown with a plurality of channels to draw sample from an underside of the separator 20 (more clearly shown in Figure 7).
- An outlet tube 178 such as but not limited to a needle can be used to engage a container such as but not limited to a sealed container with piercable septum or cap, wherein the interior or the container is under vacuum pressure therein to pull liquid sample into the container when it is flu dically engaged by the needle of the outlet tube 178.
- the container may take the form of a test tube-like device in the nature of those marketed under the trademark "Vacutainer" by Becton- Dickinson Company of East Rutherford, NJ.
- Figure 7 shows, in one embodiment, a side cross-sectional view of the device 170.
- the separator 20 is "sandwiched" between the distributor 174 and the collector 176.
- the separation material along the first pathway configured to remove formed components from the sample prior to outputting at the first outlet.
- Processed sample will be outputted through the outlet tube 178 into a container or other receptacle.
- Some embodiments as seen here may- have a tunneled portion in the collector 176 to direct sample that has been processed towards the outlet tube 178.
- the sample can be applied directly to the distributor 174 or directly to the separator 20.
- Figure 8 is a perspective view of a sample separation device 190.
- This embodiment of the sample separation device 190 is configured to allow for direct application of the sample onto the separator by way of opening 192 over the separator. Processed liquid will be drawn by the collector 194 to be output through the outlet 196.
- the sample collection device 200 includes a first pathway 202 that is configured to direct sample to a separator 204.
- the sample collection device 200 also includes a second pathway 206 that collects sample but does not direct it through a formed component separator 204.
- Both pathways 202 and 206 have openings that are co-located, adjacent, coaxial, or otherwise closely positioned at a distal end 208 of the device 200 that will be in contact with the subject.
- some embodiments may- share a common pathway that has a single opening at the distal end 208,
- the collected sample may exit from one or more adapter channels 210 to one or more sample containers (not shown for ease of illustration).
- Figure 10 shows that the distributor 212 may have features that extend beyond the area of the separator 204. These off-membrane features are helpful in drawing the sample towards and over the membrane, particularly as the channel widens to accommodate the membrane.
- Figure .1 1 is a cross-sectional view of one embodiment of the distributor 212 over the separator 204 as indicated by arrows 1 1-1 1 in Figure 30.
- the separator 204 may have reduced thickness area 234 where the material may be thinner or optionally where the material is compressed from its normal thickness to hold the material in place.
- one purpose of this compressed region is to compress the pores in the membrane and thereby create a seal that is impassable by the formed components.
- normal separator thickness may be in range of about 100 to about 1000 microns.
- normal separator thickness may be in range of about 200 to about 900 microns.
- normal separator thickness may be in range of about 200 to about 500 microns.
- normal separator thickness may be in range of about 300 to about 500 microns.
- normal separator thickness may be in range of about 300 to about 800 microns.
- normal separator thickness may be in range of about 400 to about 700 microns.
- normal separator thickness may be in range of about 500 to about 600 microns.
- Figure 1 1 also shows that the collector 216 may be a plurality of capillary channels that have a v-shaped cross- section. These are used to draw the liquid only sample to the outputs of the device at adapter channel 210.
- Figure 12 shows the device 220 as having an inlet 222 for receiving sample as indicated by arrow 224.
- the sample received at inlet 222 enters a channel 226 that is aligned along an axis configured to intersect the plane in which the separator 228 is positioned.
- the sample when it contacts the separator 228 is placed onto primarily a planar surface of the separator 228,
- the peripheral portion 230 of separator 228 is compressed to hold the separator in place and to prevent sample from exiting along the edge of the membrane, instead of through the back and into the collector 232.
- the sample contact both the separator 228 and channels 234 of the distributor 236.
- the sample is drawn by both the separator and the distributor 236 to be distributed over and/or through the separator.
- the distributor may be used to facilitate longitudinal uniformity of the sample with respect to concentration of formed components in the liquid portion of the sample.
- use of the distributor 236 can also speed the filling process.
- the channels 234 may be coupled to one or more vents 2.38 that allow for gas or air to be displaced when sample enters the distributor 236.
- each channel 234 may have its own individual vent 238.
- some embodiment may have two or more channels 234 couple to share a vent by way of common manifold configuration or the like.
- the vents are positioned at the ends of the channels 234 to allow for the channels to fully fill.
- Figure 13 shows a lateral cross-sectional view of one embodiment the device 220 wherein the channels 234 of the distributor 236 are shown over the capillary collection channels 240 of the collector 242.
- Figure 13 also shows that not ever channel in the collector 242 has the same cross-sectional shape.
- the channels 244 along a perimeter of the collector 242 may have a different shape such as but not limited to a rectangular cross-section that is different from other channels in the collector 242.
- FIG 14 a cross-sectional view of one embodiment of a sample inlet channel will now be described.
- the inlet channel 226 directs sample from inlet 222 towards the separator 232.
- the angled orientation of channel 226 relative to the plane of the separator 232 allows for sample to be placed onto the planar surface of the separator and not relying purely on lateral pulling.
- the angled cross-sectional shape also increases the area of sample contact to be greater than merely the lateral cross-section of the channel.
- Figures 15 and 16 also show other embodiments wherein sample inlet channels 250 and 252 that have sample channel transition features 254 and 256 that minimize detrimental effects due to change in channel dimension.
- These transitions features may be configured to reduce dimension in one axis (feature 254) or minimize a sudden change in dimension (feature 256) by gradually transitioning the change in dimension over a longer and/or wider area. It should be understood that some embodiments may combine the use of features 254 and 256. Other embodiments herein may also have these features or others that use embody the concepts described herein to minimize detrimental impact of certain channel features.
- Inlet channel desirably leads to direct contact with the membrane, which in one non-limiting example, is without an intermediary reduction in capillary forces, which can stop the blood flow and prevent distribution.
- Figure 17 shows an angled sample inlet channel 260 that has a "splitter" configuration wherein at least one opening of channel 262 co uples with the inlet channel 260 to direct a portion of the sa mple to channel 262.
- the opening for channel 260 is at least as large as if not larger than the cross-sectional shape of the inlet channel 260.
- the sample continues in a second portion 264 of the inlet channel 260 to reach the separator 232.
- the openings 266 of a distributor for the separator 232 can be located at the end portion of the channel 260.
- the second portion 264 of channel 260 is smaller in cross- sectional area than an initial portion of the channel 260.
- Figure 17 also shows that the channel 260 is directing sample at an upper portion of the channel profile to the second portion 264 while the opening for channel 262 collect at least sample in the lower portion of the channel profile.
- a higher entry point can help with lengthwise blood distribution along the length of the separator by delaying and reducing initial penetration of the separator by the sample as it flows into the distribution volume.
- Figure 18 shows yet another embodiment of the sample inlet channel wherein the opening for channel 263 is now configured to interface only a smaller portion of the channel 260. As seen in Figure 1 8, the opening 263 of the channel intersects only a lower portion of the channel profile for channel 260. This can useful to customize the volume of sample that is directed towards each channel.
- FIG. 19 shows yet another embodiment wherein the inlet channel 270 connects to the second channel 272 and has a significantly larger cross-sectional profile relative to the second portion 274 of the inlet channel.
- the second portion 274 is configured to draw sample from an upper portion of the cross-sectional profi le of the inlet channel.
- the openings 276 for the sample distributor draw from the lower portion of the portion 274 to distribute sample over the separator 232.
- a collector 278 will draw liquid sample from the separator 232.
- At least one vent 280 can be coupled to the separator 232 to provide a controlled inlet of external atmosphere to facilitate the pull of liquid device, in one non-limiting example, vent 280 may allow at least some venting to occur during the dynamic stage of extraction, in which a pressure differential or other motive force is applied to draw the liquid portion of the sample into at leasi one collection container.
- the vent 280 may be separated from the collector 278 by the separator 232 to provide a controlled inlet.
- the vent 280 may couple to compressed portion of the separator 232.
- the vent 280 may couple to normal portion of the separator 232.
- Figures 20 and 21 various shapes can be configured for use to engage a subject for sample collection according to embodiments herein.
- Figures 20 and 21 both show protrusions for use on collection devices as described herein.
- Figure 20 shows a protrusion 290 that is shaped in a scoop or spoon configuration having both vertical and horizontal portions of the opening 292 in the protrusion accessible to the user to collect sample.
- the opening 292 may lead to a single or multiple pathways in the device.
- FIG. 21 shows one embodiment of a protrusion 294 that extends away from the body of the device so that the user is provided a visual cue as to where the contact the device to the subject to collect sample.
- the opening may be funnel shaped to assist in sample collection and in engagement with the skin of the patient.
- the protrusion 294 has an opening that may l ead to a single or multiple pathways in the device. It should be understood that some embodiments may have protrusions that are shaped to be convex or concave to facilitate engagement of the device protrusion with bead or droplet of bodily fluid sample on the subject.
- the protrusion may be coated with hydrophilic and/or hydrophobic material to push or pull the sample in a desired direction.
- sample can be delivered to one or more different locations on the sample separator according to at least one embodiment herein. As seen in F gures 19 to 21 , some embodiments may deliver sample to one end of the separator, away from a central portion of the separator. Optionally, some embodiments as seen in Figures 22 to 23, deliver sample from an inlet at one end to one or more openings closer to the center of the separator. The sample may be delivered both at the one end and at locations closer to the center.
- Figure 2.2 shows embodiments of inlet tubes 310, 312, and 314 for use in delivering sample from an inlet on a periphery of the device to one or more locations along a central area of the separator 316.
- the locations 320, 322, and 324 may be openings or other structures that allow the inlet tubes 310, 312, and 334 to deliver sample to the desired location on the separator 316,
- Figure 22 shows that these locations may be distributed over various locations on the separator 316.
- Figure 23 shows an embodiment wherein the locations 330, 332, and 334 are located in a line near the central area of the separator.
- some embodiments may use single or multiple combinations of one or more of the structures in Figures 19 to 24 to provide a desired sample distribution pattern over the separator. It should be understood that the embodiments herein can deliver the sample directly onto the separator, onto network of distributor channels over the separator, or a combination of the foregoing.
- Figure 2.4 shows a still further embodiment wherein the inlet is not located at either end of the collection device, but instead has an inlet that is substantially centrally located as seen in Figure 24.
- This embodiment shows that the inlet 340 leads to a channel 342 that feeds to a central portion of the separator 344.
- Figure 24 is a simplified drawing showing primarily only the separator 344 and an outlet port 346 that draws liquid portion of the sample away from the separator after processing.
- the distribution of the channels of the distributor is not limited to the patterns, sizes, or shapes disclosed in the previous figures.
- one embodiment may align ail of the channels 350 orthogonal to the longitudinal axis of the device and/or separator, in the embodiment of Figure 25, this results in a greater number of channels 350, but each has a shorter length.
- the orientation of the channels is not limited to orthogonal to the longitudinal axis of the device. Other angles relative to the longitudinal axis of the device and/or the separator are not excluded.
- some embodiments may use different patterns over different portions of the separator.
- some embodiments can use a combination of patterns over the same area.
- this same or similar pattern of channels can also be implemented on the collector that is used on the opposite side of separator.
- the distributor can use one channel pattern and the collector can use a different channel pattern.
- some of the sideways capillaries 350on the collector uses a non- vented configuration.
- Some of these sideways capillaries 350 demonstrated a different extraction behavior as blood separates. Lengthwise capillaries tend to extract from back of device first, then towards the front. Sideways capillaries 350 extract first towards the middle of the separator and outwards towards front and back of device, which can be used to create a more even extraction process across the separator.
- some embodiments may also use a configuration having a manifold 360 having a plurality of outlets 362 that can distribute sample over the separator and/or into the distributor. Some embodiments can have shorter or longer outlets 362, depending o the pattern that one desires to deliver sample to the separator and/or distributor. Tt should also be understood that some embodiments may more than one manifold 360 that delivers sample to the separator and/or distributor. For example, one embodiment may have another manifold 360 deliver sample along the other longitudinal edge of the separator.
- Figure 26 also shows in phantom a potential pattern for a collection manifold 364 for use on the opposite side of the separator for sample collection.
- This manifold 364 would typically not be used on the same side as the distribution manifold 360 but would instead be on an opposite side of the separator.
- FIG. 27A a still further embodiment is shown with a patterned manifold 370 with channels that distribute sample along various locations over the separator 372.
- Figure 27 A shows that there may be a plurality of vents 374 that allow for gas or air in the separator 372. or other part of the manifold to escape as sample fills the area.
- the manifold 370 is shown with a distribution pattern of substantially similar length channels 376, such channels can be pattern to have same, different, repeating, or other patterns of size, length, contact area with the separator, or other dimension to provide a desired performance.
- the manifold 370 can be used to directly distribute sample onto the separator or it may opt to deliver sample in a pattern to a distributor which then further distributes the sample over the separator.
- Some embodiments of the manifold 370 uses tubes with openings at select locations to allow sample to exit.
- Some embodiments can use channels with at least one open side to distribute sample along a certain length of the separator and/or distributor.
- FIG. 27B a still further embodiment is shown with a patterned manifold 371 with channels that distribute sample along various locations over the separator 372.
- the manifold 371 is shown with a distribution pattern of substantially channels 377, such channels can be pattern to have same, different, repeating, or other patterns of size, length, contact area with the separator, or other dimension to provide a desired performance.
- this embodiment with manifold 371 uses shorter length channels 377 as compared to channels 376 of manifold 370.
- Figure 27B also shows that embodiments of the manifold 371 may include multiple longer length channels 378 to distribute sample to the intersection channels 377.
- Figure 27B shows there are three channels 378, but it should be understood that other embodiments may have a different number of channels. It should also be understood that the manifold 371 can be used to directly distribute sample onto the separator or it may opt to deliver sample in a pattern to a distributor which then further distributes the sample over the separator. Some embodiments of the manifold 371 uses tubes with openings at select locations to allow r sample to exit. Some embodiments can use channels with at least one open side to distribute sample along a certain length of the separator and/or distributor.
- FIG 28 yet another embodiment of a manifold 380 is shown.
- This can be as a distributor that has twelve channels that distribute sample over the separator.
- the channel patt ern of manifold 380 initially has six channels leading away from a single inlet channel, and those six channels are each split once to achieve twelve channels.
- Figures 29 to 34 show a single inlet 390 having a circular cross-sectional shape leading to a multi-channel distributor 392 with channels 394, with each of the channels coupled to its own vent 396, similar to that shown for Figure 12. It should be understood, however, that embodiments where vents are shared are not excluded.
- Figure 30 shows the cross-sectional shape of the channels 394 and their size relative to the capillary channels 398 of the liquid sample collector.
- Figures 31 and 32 show at least one embodiment of an inlet channel 400 having a low aspect ratio in terms of channel height to width.
- the narrow height, wide inlet channel 400 leads to a multi-channel distributor 402, wherein the channels 404 also have low height to width aspect ratios and also have intersecting connectors 406 that provide connector pathways between the channels to form a grid or other pattern.
- the connectors 406 are pathways with narrower cross-sectional areas that of the channels 404.
- Each of the channels 404 is coupled to its own vent 408, but it should be understood that embodiments where vents are shared are not excluded.
- the lo a spect ratio of the channels 404 are more clearly shown in Figure 32 along with their cross-sectional area relative to the cross-sectional area of the channels 409 of the collector.
- FIGs 33 and 34 show an embodiment having an inlet 420 comprising a plurality of individual channels 422. that are co-located as the inlet 42.0.
- each of inlet channels 422 directs its portion of the sample to the distributor 424, which in this case is a multi-channel distributor, wherein the channels 426 have intersecting connectors 428 that provide connector pathways between the channels to form a grid or other pattern.
- the connectors 42.8 are pathways with at least the same or greater cross-sectional area than that of the channels 426.
- Each of the channels 426 is coupled to its own vent 429, but it should be understood that embodiments where vents are shared are not excluded.
- the low aspect ratio of the channels 426 are more clearly shown in Figure 34 along with their cross-sectional area relative to the cross-sectional area of the channels 430 of the collector.
- the separators are shown with its upper surface in contact at location 427 with a wall surface of the device so that there is no gap.
- Some embodiments may- have the separator under compression to maintain this contact and to account for any variation due manufacturing tolerances. This contact may also be true for the surfaces below the separator.
- this vertical compression of the separator to overcome any manufacturing tolerances can be applied to any of the embodiments discussed or suggested herein.
- the separator may be configured to be in certain Häe dimensional configurations such as but not limited to tubular, cylindrical, disc, pyramid, mesa, or the like can also be adapted for use herein.
- some inlet locations 440 for sample distribution are shown for some embodiments. These are merely exemplary and other positioning of the number and location of inlets 440 are not excluded.
- the sample continues to fill the separator 232 with the multi-mode sample propagation pattern as seen in Figure 37 until the fill is completed as seen in Figure 38, when sample is filled in the channels to reach the vents 238.
- the volume of sample in the channels is greater than that in the separator 232 and this may account for part of the reason that the leading edge in the separator 232 may be moving ahead of that in the channels 234.
- a pulling force such as but not limited to full or partial vacuum in a sealed container like a vacutainer can be used to start moving liquid only sample into the container. As long as there is no " ⁇ meniscus" break or if such breaks are recoverable, the sample still in the separator 232 or above it will begin to be drawn though the device.
- Figure 40 shows that some sample that was in the inlet 2.22 has been drawn into the channels 2.34. Sample has begun to drain into the separator 232 in the channels 234 closest to the edge near the pulling force indicated by arrow 460.
- Figure 41 also shows that the sample continues to be drawn downward and in the direction of arrow 460, there is also movement of sample further away from the inlet 222.
- Figure 42 shows that upon completion of the separation process, form components such as but not limited to red blood cells that have been size-excluded from the sample remain and leave a light red color on the separator 232.
- FIG. 43 shows that maximum trans separator pressure occurs closest to the end of the device where the outflow 460 is occurring. The further away from the area of outflow 460, the lesser the trans pressure across the separator. This gradient can explain in part the flow pattern seen in Figures 39-42.
- one embodiment herein comprises at least one or more vents 470 on the back side/collector side of the collector that decouples filtration from extraction.
- the controlled venting is balanced by having the pathway to reach the vent 470 pass through a portion of the separator 232. In one embodiment, this is a portion of the separator 232 is not filled with sample.
- this is a compressed portion of the separator 232 not filled with sample.
- the resistance is substantially equal to the resistance associated with venting through the separator 232 filled with sample. In one embodiment, the resistance is less than the resistance associated with venting through the separator 232 filled with sample.
- FIG. 45 shows that in this embodiment, the vent 480 is coupled to a shaped pathway 482 that is configured to be in communication with the capillary channels 240 of the collector 242.
- Some embodiment may include a valve, porous material, mesh material, reduced diameter pathway, or other flow reducing material to control the flow of air from the vent to the interior of the collector 242.
- Some embodiments may also have the shaped pathway 482 be compressed with material from the separator (not shown) to slow the flow to the collector 242.
- the vent 484 of this embodiment is coupled to a shaped pathway 486 that is configured to be in the area where the separator material (shown in phantom by line 487) will cover it.
- the coverage may be in a compressed manner.
- the coverage may be without substantial compression.
- the communication with the capillary channels 350 of the collector are separated by a pre-selected distance 488 from the shaped pathway 486 of the vent. In this manner, the pathway travels through at least that distance 488 of separator material (which may be gas porous) before air from the vent is able to be in fluid communication with the channels 350. This can be useful in some embodiments to regulate the rate in when venting occurs.
- shaped pathways 482 and 486 are shown as continuous pathways, they may optionally be a plurality of discontinuous, discrete openings linked to a common vent or having their own individual vents. In some embodiments, it is desirable to locate the vent near the end of the device distant from the end where liquid sample is being pulled from the device. Some embodiments may combine one or more components of Figures 45 and 46 together regarding venting and regulation of air through any such vent,
- Figures 47 and 8 show cross-sectional views of the separator showing different percentages of saturation by the sample.
- the spacing of the channels of the distributor over the separator can be selected to increase separator saturation.
- Figure 47A shows large channels spaced farther apart yields lower saturation ihai a combination of smaller channels spaced closer together to achie ve a more uniform saturation pattern in the material,
- directed wetted area 490 as compared to indirectly wetted area 492 can be configured to increase overall saturation of the separator.
- the directly wetted surface area in Figure 47B relative to total surface area is about 30%.
- Figure 48B shows directed wetted area 492 as compared to indirectly wetted area 496 can be configured to increase overall saturation of the separator.
- the directly wetted surface area in Figure 48B relative to total surface area is about 60%.
- Channels in the new configuration have a larger ratio of directly wetted surface area (DWA) to volume V, and nearly twice the directly wetted area as a fraction of total surface area (SA), wherein V is the volume of the separator. This results in a more effective wetting of the membrane; takes in more liquid per surface area.
- the desired range of channel surface area relative to the surface area of the separator on that side of the separator is in the range of about 35% to 70%.
- the desired range of channel surface area relative to the surface area of the separator on that side of the separator is in the range of about 40% to 70%,
- the desired range of channel surface area relative to the surface area of the separator on that side of the separator is in the range of about 50% to 60%.
- the ratio of Channel SA/V which is also DWA V is in the range of about 5 to about 10.
- the ratio of Channel SA/V which is also DWA/V is in the range of about 4.5 to about 9.
- the ratio of Channel SA/V which is also DWA/V is in the range of about 5 to 8.
- the ratio of Channel SA/V which is also DWA/V is in the range of about 6 to 8
- the ratio of Channel SA/V which is also DWA/V is in the range of about 5,5 to 7.
- the ratio of Channel SA/V which is also DWA/V is in the range of about 6 to 7.
- Figure 49 shows an embodiment wherein there are no channels over the separator 20
- Figure 50 shows an embodiment with ten channels. Although distributed symmetrically about a longitudinal axis of the separator, it should be understood that other embodiments where channel size, distribution, or length are not symmetrical about the longitudinal axis may be used.
- Figure 51 shows an embodiment with twenty two distribution channels.
- Figure 52 shows a plurality of cross-sections of the device showing the distributor, separator, and collector.
- the channels 500 of the distributor can be of various cross-sectional shapes such as but not limited to elliptical, triangular, quadrilateral (e.g., square, rectangular, trapezoidal, parallelogram), pentagonal, hexagonal, heptagonal, octagonal, square, circular, star, other two dimensional patterns, oval, half-oval, half-circular, polygonal, or single or multiple combinations of the foregoing.
- the lengthwise pathway shape can also be configured such as to distribute sample in a desired manner o ver the separator.
- the channels 510 of the collector can be of various cross-sectional shapes such as but not limited to elliptical , triangular, quadrilateral (e.g., square, rectangular, trapezoidal, parallelogram), pentagonal, hexagonal, heptagonal, octagonal, square, circular, star, other two dimensional patterns, oval, half-oval, half-circular, polygonal, or single or multiple combinations of the foregoing.
- the channels shapes of the distributor and the collector may be the same or different.
- Some embodiment of the distributor may have different shaped and'Or sized channels in the distributor to provide a certain desired sample distribution pattern.
- Some embodiment of the collector may have different shaped and/or sized channels in the collector to provide a certain desired sample collection pattern.
- Figures 53 to 55 show various non-limiting examples of different aspect ratios for the separators for use with the device.
- Figures 53 and 55 also show different aspect ratios for the distributor used with such a device.
- the separator has a configuration where the aspect ratios, defined as the length of the separator 520 (lengthwise along the direction of flow, toward the extraction port as indicated by arrow 521) divided by its width along arrow 523 are in the range of about 1 : 1 to 3 : 1.
- the aspect ratio may be in the range of 1 : 1 to 5: 1 .
- some embodiments may have aspect ratios in the range of 5 : 1 to 1 : 1.
- the channels 500 are shown over the separator 520.
- a common vent 530 which is shown in Figures 53 and 54 can be also adapted for use with other
- Figure 55 shows a plurality of different aspect ratios for the separator 520 and the distributor having channels 500.
- Figure 56 shows one example of an exit conduit 540 below the collector 550 that shows a round inner surface 542. in the 90 degree elbow that transitions directions of sample flow out of the device from a vertical to a lateral flow,
- Figures 57 to 59 show that in addition to the pathway 600 for separation of formed components from the sample, some embodiments of the device are also configured to allow for other pathways 610, 620, or 630 that collect sample for treatment in a different manner. As seen in the figures, these pathways can be shaped and sized so that they can contain a desired amount of sample therein. Some embodiment may be configured so that the pathlength is such that the fill times for both the formed component separated sample and the un-separated sample are substantially the same. In this manner, a single indicator can be used to alert the user that sufficient fill has been achieved in both pathways.
- Figures 57 to 59 also show that the output of the devices may be into containers 660.
- the container may be but is not limited to a sealed container with piercabie septum or cap, wherein the interior or the container is under full, partial, or some level of vacuu pressure therein to pull at least a certain volume of liquid sample into the container when it is fluidicaliy engaged by the needle of the outlet tube or needle of the devices described herein.
- the container ma take the form of a test tube-like device in the nature of those marketed under the trademark "Vacutainer" by Beeton-Dickinson Company of East Rutherford, NJ.
- the output of one device may be both blood (B) and plasma (P).
- the output can be viewed as a) separated liquid-only sample and b) other sample output.
- the output can be viewed as a) separated liquid-only sample (and any formed components smaller than the size exclusion limit) and b) other sample output.
- One or more of the pathways may be treated, coated, or otherwise prepared to deliver a material into the sample such as but not limited to an anti-coagulant, ethylenediaminetetraacetic acid (EDTA), citrate, heparin, or the like as currently known or will be developed in the future. Some may have two or more the pathways treated with the same or different material.
- Figure 59 shows a still further embodiment showing a Y-split to separate sample to go in to both pathways.
- this indication of fill le vel in one or more of the pathways may be by way of a visual indication. It should also be understood that other indication methods such as but not limited to audio, vibratory, or other indication methods may be used in place of or in combination with the indication method.
- the indicator may be on at least one of the collection pathways. Optionally, indicators are on all of the collection pathways. It should be understood that the devices herein can be configured to have three or more pathways and are not limited to only two pathways.
- container(s) such as but not limited to container 660 for use in drawing liquid sample that has gone through or will be drawn through the separator.
- this is a two phase process, where there is an initial filling phase of sample into the separator using a first motive force and then a second phase using a second motive force to complete the sample separation process.
- the at least two different motive forces can be sensitive to timing in that it may be undesirable to activate the second motive force until a sufficient volume of sample has been metered into one or more of the pathways or until a sufficient fill allows for drawing of sample into the container without a meniscus break during the draw process under the second motive force.
- Suitable methods, devices, features, indicators, or the like can be found in U.S. Patent Application Ser. No.
- Figure 60 shows a still further embodiment wherein the output tube, needle, channel, or other structure 670 can be oriented to exii from a bottom part of the device. It can be orthogonal to the plane or at other angles. Some embodiments may have both bottom and side exiting output structures 670. Some embodiments may have multiple output structures 670 in side and/or bottom surfaces.
- the collection and/or separation pathways such as but not limited to channels may also have a selected cross-sectional shape. Some embodiments of the pathways may have the same cross-sectional shape along the entire length of the pathway.
- the cross-sectional shape may remain the same or may vary along the length.
- some embodiments may have one shape at one location and a different shape at one or more different locations along the length of the pathways.
- Some embodiments may have one pathways with one cross-sectional shape and at least one other pathway of a different cross- sectional shape.
- some may have a circular, elliptical, triangular, quadrilateral (e.g., square, rectangular, trapezoidal), pentagonal, hexagonal, octagonal, or any other cross-sectional shape.
- the cross-sectional shape may be the same for the body, support, and base, or may vary.
- Some embodiments may select a shape to maximize volume of liquid thai can be held in the pathways for a specific pathway width and/or height. Some may have one of the pathways with one cross-sectional shape while another pathway has a different cross-sectional shape.
- the cross-sectional shape of the pathway can help maximize volume therein, but optionally, it can also optimize the capillary pulling forces on the blood. This will allow for maximized rate of filling. It should be understood that in some embodiments, the cross-sectional shape of the pathway can directly affect the capillary forces.
- a volume of sample can be contained in a shallow but wide pathway, or a rounded pathway, both containing the same volume, but one might be desirable over the other for filling speed, less possibility of air entrapment, or factors related the performance of the pathway,
- the pathways may have any shape or size, some embodiments are configured such that the pathway exhibits a capillary action when in contact with sample fluid.
- the pathway may ha ve a cross-sectional area of less than or equal to about 10 mm 2 , 7 mm 2 , 5 mm 2 , 4 mm 2 , 3 mm 2 , 2.5 mm 2 , 2 mm 2 , 1.5 mm 2 , 1 mm 2 , 0.8 mm 2 , 0.5 mm 2 , 0.3 mm 2 , or 0.1 mm 2 .
- the cross-sectional size may remain the same or may vary along the length. Some embodiments may tailor for greater force along a certain length and then less in a different length.
- the cross-sectional shape may remain the same or may vary along the length. Some pathways are straight in configuration. Some embodiments may have curved or other shaped path shapes alone or in combination with straight portions. Some may have different orientations within the device body. For example, when the device is held substantially horizontally, one or more pathways may slope downward, slope upward, or not slope at all as it carries fluid away from the initial collection point on the device.
- the inner surface of the pathway and/or other surfaces along the fluid pathway such as but not limited to the sample inlet to the interior of a sample collection vessel may be coated with a surfactant and/or an anti -coagulant solution.
- the surfactant provides a wettable surface to the hydrophobic layers of the fluidic device and facilitate filling of the metering pathway with the liquid sample, e.g., blood.
- the anti-coagulant solution helps prevent the sample, e.g., blood, from clotting when provided to the fluidic device.
- Exemplary surfactants that can be used include without limitation, Tweeii, TWEEN®20, Thesit®, sodium deoxy chelate, Triton, Triton®X- 100, Pluronic and/or other non-hemolytic detergents that provide the proper wetting characteristics of a surfactant.
- EDTA and heparin are non-limiting anti-coagulants that can be used.
- the embodiment the solution comprises 2% Tween, 25 mg/mL EDTA in 50% Methanol/50% H20, which is then air dried.
- a methanol/water mixture provides a means of dissolving the EDTA and Tween, and also dries quickly from the surface of the plastic.
- the solution can be applied to the pathway or other surfaces along the fluid flow pathway by any technique that will ensure an even film over the surfaces to be coated, such as, e.g., pipetting, spraying, printing, or wicking.
- a coating in the pathway may extend along the entire path of the pathway.
- the coating may cover a majority but not all of the pathway.
- some embodiments may not cover the pathway in the areas nearest the entry opening to minimize the risk of cross-contamination, wherein coating material from one pathway migrates into nearby pathways by way of the pathways all being in contact with the target sample fluid at the same time and thus having a connecting fluid pathway.
- embodiments herein are shown with two separate pathways in the sample collection device, it should be understood that some embodiments may use more than two separate pathways. Optionally, some embodiments may use less than two fully separate pathways. Some embodiments may only use one separate pathway. Optionally, some embodiments may use an inverted Y-pathway that starts initially as one pathway and then splits into two or more pathways. Any of these concepts may be adapted for use with other embodiments described herein.
- one or more of the pathways may be coated with a material to be incorporated into the sample.
- one of the pathways fills first before the unfiltered/separated pathway fills, in one embodiment, the sample volume in one pathway is greater than the sample volume in the other pathway. In one embodiment, the sample volume in one pathway is greater by Ix than the sample volume in the other pathway.
- a cap may attach to the collection device using any technique known or later developed in the art.
- the cap may be snap fit, twist on, friction-fit, clamp on, have magnetic portions, tie in, utilize elastic portions, and/or may removably connect to the collection device body.
- the cap may form a fluid-tight seal with the collection device body.
- the cap may be formed from an opaque, transparent, or translucent material.
- the collection device body of the sample collection and separation device may be formed in whole or in part from an optically transmissive material.
- the collection device body may be formed from a transparent or translucent material such as but not limited to Poly(methyi methacrylate) (PMMA), Polyethylene terephthalate (PET), Polyethylene Terephtaiaie Glycol-modified (PETG or PET-G), or the like.
- PMMA Poly(methyi methacrylate)
- PET Polyethylene terephthalate
- PET-G Polyethylene Terephtaiaie Glycol-modified
- the body comprises an opaque material but an opening and/or a window can be formed in the body to show fill levels therein.
- the collection device body may enable a user to view the channels within and/or passing through the device body.
- the channels may be formed of a transparent or translucent material that may permit a user to see whether sample has traveled through the channels.
- the channels may have substantially the same length.
- a support may be formed of an opaque material, a transparent material, or a translucent material. The support may or may not have the same optical characteristics of the collection device body.
- the support may be formed from a different material as the collection device body, or from the same material as the collection device body. [00163]
- the collection device body may have any shape or size.
- the collection device body may have a circular, elliptical, triangular, quadrilateral (e.g., square, rectangular, trapezoidal), pentagonal, hexagonal, octagonal, or any other cross-sectional shape.
- the cross-sectional shape may remain the same or may vary along the length of the collection device body.
- the collection device body may have a cross-sectional area of less than or equal to about 10 cm 2 , 7 cm 2 , 5 cm 2 , 4 cm 2 , 3 cm 2 , 2.5 cm 2 , 2 cm 2 , 1.5 cm 2 , 1 cm 2 , 0.8 cm 2 , 0.5 cm 2 , 0.3 cm 2 , or 0.1 cm 2 .
- the cross-sectional area may vary or may remain the same along the length of the collection device body 120.
- the collection device body may have a length of less than or equal to about 20 cm, 15 cm, 12 cm, 10 cm, 9 cm, 8 cm, 7 cm, 6 cm, 5 cm, 4 cm, 3 cm, 2 cm, 1 cm, 0.5 cm, or 0.1 cm.
- the collection device body may have a greater or lesser length than the cap, support or base, or an equal length to the cap, support, or base.
- FIG. 61 a still further embodiment of a sample collection and sample separation device will now be described.
- This embodiment shows a cartridge 1400 with a sample collection and sample separation device 1402 integrated therein having one or two pathways 700 and 702.
- the device 1402 may be integrally formed with the cartridge.
- it may be a separate unit that this is removable from the cartridge.
- it may be a separate unit that this is added to the cartridge after sample has been collected from the subject.
- it may be a separate unit that this is added and/or attached to the cartridge and sample is collected from the subject after the unit it added and/or attached to the cartridge,
- sample handling device there is a collection location 1322 and one or more sample openings 1325and 1329 where sample collection at location 1322. can then be accessed such as but not limited to handling by a pipette tip (not shown).
- the sample from droplet D will travel along pathway 1326 as indicated by arrow towards the openings 1325 and 1329, where the sample in the opening and any in the pathways 1324 and/or 1326 leading towards their respective openings 1325 and 1329 are drawn into a sample handling system such as but not limited to a pipette P.
- a vacuum or suction by the sample handling device can be used to fully dra sample though the separator 720 and complete the separation process.
- the pipette P is movable in at least one axis to enable transport of sample fluid to the desired location(s).
- the cartridge 1400 can have a plurality of holding containers 1410 for reagents, wash fluids, mixing area, incubation areas, or the like.
- some embodiments of the cartridge 1400 may not include any holding containers or optionally, only one or two types of holding containers.
- the holding containers may be pipette tips.
- the holding containers are pipetie tips that are treated to contain reagent(s) on the tip surface (typically the interior tip surface although other surfaces are not excluded).
- some embodiments of the cartridge 1400 may include only the sample collection device 1402 without the tissue penetrating member or vice versa.
- a suitable device for use with cartridge can be found in U.S. Pat. App. Ser. No. 13/769,798, filed February 18, 2013. it should be understood that some embodiments may be configured to have only one of the above pathways in the sample collection and/or sample separation device. Some may have more than two of the pathways. Some may have more than one separator per pathway . Some may have multiple pathways each with one or more separators.
- Some embodiments may use the sample handling device such as but not limited to the pipette P to draw sample towards or onto the separator and then use the pipetie to draw sample out of the underside or other side of the processor after the sample has been or has begun to be separated.
- the sample handling device such as but not limited to the pipette P to draw sample towards or onto the separator and then use the pipetie to draw sample out of the underside or other side of the processor after the sample has been or has begun to be separated.
- FIG. 62 a perspective view is shown of a still further embodiment showing a device such as a fluid circuit portion 800 with extraction ports 802 and 804.
- the embodiment of Figure 62 uses a single inlet 806 to direct portions of the sample to two different pathways, wherein at least one portion passes through a formed component separation member.
- FIG. 63 a perspective view is shown of a still further embodiment showing a device with fluidic circuit portion 800, a housing portion 822, and a sample container unit 824.
- this non-limiting sample shows housing portion 822 coupling the fluidic circuit portion 800 with the sample container unit 824.
- the housing portion 822 allows for the sample container unit 824 to be coupled to the same fluidic circuit portion 800 but still have the sample container unit 824 movable between a first position (as shown in Figure 63) and a second position.
- an inlet port centered along a mid-line of the fluidic circuit with an entry point on to the formed component separation member that is off-center relative to the midline of the formed component separation member.
- a vent channel of a curved configuration is coupled to a vent channel with a curved portion and an intersection linear (bent or straight) portion.
- the vents in this non-limiting example are collection features that are on the side of the separation member were fluid, but not formed components, can exit the membrane.
- a vent channel has a linear (bent or straight) portion coupled to a distribution portion, wherein the linear portion is closer to an external vent and distribution portion is closer to the separator.
- Figure 64 shows structures with sharp corners 890 while Figure 65 shows an embodiment with radii or rounded corners 892.
- tangency and curvature of the rounded corners 892 may provide continuous liquid contact to assist with fluid flow out of a separation member such as but not limited to a membrane and into an opposing portion of the fluid circuit such as but not limited to the capillary flow structure. It should be understood that the round comers 892 creates at least one transition region 894 which can assist drawing or leaching of fluid from one region towards the fluid collection structures in the device. In some embodiments, this drawing or leaching of fluid out of the separation member can be desirable.
- the embodiments with a sharp comer 890 which opens directly the capillary structure with a transition region diminishes the assistance that may come from have the closely spaced area associated with the tangency and curvature provided by rounded corners 892.
- some embodiments may have a sharp corner 896 but further include at least one transition region that may provide continuous liquid contact to assist with fluid flo out of the separation member.
- some embodiments may have at least one increased width region between the capillary structure 898 and the transition region 894.
- the capillary structure may be formed of or have a surface treated to create a hydrophiiic fluidic structure.
- the structure can be made of a hy drophiiic material such as but not limited Poly ethylene terephtbalate glycoi-rnodified (PET-G) which has a small wetting angle and is a hydrophiiic material which can draw fluid toward the back side of the membrane.
- PET-G Poly ethylene terephtbalate glycoi-rnodified
- some embodiments may use cellulose acetate, cellulose acetate butyrate, or other suitable material.
- Plasma collection vent more plasma without hemolysis; distributors also are; capillary structures on the back side membrane.
- the other vent blood side / distributor vents
- the other vent blood side / distributor vents
- inlet flow control features may be used in the sample container to control the rate and/or amount of motive force applied to filtered sample and/or sample about to be filtered. It should be understood that hemolysis will corrupt the sample for many assays and is thus generally undesirable.
- some embodiments may go without a dual channel inlet and use a single channel Some embodiments may ha v e an opening over (he membrane, instead of at one end.
- this embodiment can have a passive, always open vent instead of a valve.
- some alternate extraction methods may include: providing a much higher extraction vacuum (crimp opening to meter pull forces, wherein the crimp results in a 5 to 10 micron wide opening in the tube, almost a cold weld when cutting so as to form a flow regulator).
- a much higher extraction vacuum crimp opening to meter pull forces, wherein the crimp results in a 5 to 10 micron wide opening in the tube, almost a cold weld when cutting so as to form a flow regulator.
- the amount of friction can provide sufficient mechanical resistance from rapidly pushing sample vessel rapidly into the holder.
- the friction can be from the plunger, an external guide, and/or other component to provide a controlled movement between a first position and a second position.
- Other mechanical mechanism can be used to regulate speed that the user pushes it on.
- On the non-separator side in one non-limiting example, there is no plunger.
- One embodiment may use deflected point needle that is anti-coring and also provides a side opening needle tip.
- the anti-coring is desirable to prevent coring of the frit, which may introduce undesirable frit parts into the sample.
- the needle pierces through the frit. It should be understood that the frit is sized to co ver or at least substantially cover the opening of the needle pointed tip opening.
- the plunger may have a harder portion in the center while a circumferential portion is softer for liquid seal performance.
- the capillary channels with fluid therein can also settle a bit before being engaged to be extracted.
- This delayed fill of the non-separator side ensures that the separator side has filled and had some settling time before being engaged to the sample collection unit for fluid transfer into the sample collection unit.
- 80 microliters of whole blood results in 16 to 20 microliters of plasma.
- FIG. 68 a cross- sectional view is shown of one non-limiting example wherein an inlet channel 808 is shown penetrating one non-limiting example of a sample container unit 824.
- the movement of the plunger 828 of the sample container unit 824 can he used to create a motive force such as but not limited to at least a partial vacuum to draw liquid from the channel 808 into the sample container unit 824.
- a motive force such as but not limited to at least a partial vacuum to draw liquid from the channel 808 into the sample container unit 824.
- this increases the interior volume 829 of the sample container unit 824 between the cap portion 832.
- extracting fluid from the channel 808 may involve using one or more additional motive forces. It should be understood that this configured described herein may be similar to a reverse plunger. Optionally, some embodiments may use a conventional plunger, in place of or in combination with the structures herein, to provide motive force to draw r sample into the sample container.
- Figure 68 also shows that, in at least one embodiment, the channel 808 may have a pointed distal end 834. Still further embodiments may have the channel 808 be of a non-coring design so as not to introduce any cored portion or debris of the cap 832 into the collected fluid. Regardless of whether a non- coring, conventional, or other shaped channel 808, it should be understood that some embodiments of plunger 828 may have a hardened core portion 838 that can withstand force input from the channel 808. As seen in Figure 68, at least some embodiments of plunger 828 may have a hardened core portion 838 that can withstand force input from the channel 808. As seen in Figure 68, at least some embodiments of plunger 828 may have a hardened core portion 838 that can withstand force input from the channel 808. As seen in Figure 68, at least some
- embodiments will have a compliant material between the hardened core portion 838 and the side walls of the sample container so as to provide at least a sufficient fluid seal as the plunger 828 is moved from at least a first position to at least a second position,
- inlet design of inlet 806 may include flow guide structures 910 and 912 such as one or more small capillary channels in the sides of the inlet 806 encourage flow to enter pathway leading to the separation member, rather than the pathway without the separation member.
- the flow guide structures 910 and 912 are located as positions along the inlet 806 that have surfaces that extend toward the separation component 920.
- the fluid guide structures 910 and 912 are not along the bottom surface of the inlet, which may be where the other channel connects to the inlet, in one non-limiting example, the fluid guide structures 910 and 912 are not positioned along a surface of the inlet where the other channel connects to the inlet.
- Figure 69 shows that the inlet 806 has at least two flow guide structures 910 and 912, it should be understood that some embodiments may only have a single flow guide structure. Optionally, some embodiments may have more than two flow guide structures.
- some embodiments may have a single structure at the inlet 806 but forks into two or more structures as the fluid flows deeper into the inlet.
- some embodiments may have a plurality of fluid guide structures wherein at least two of the structures merge together so that there are fewer guide structures as the fluid flow deeper into the structure. It should be understood that some embodiments may take a plurality of guide structures and merge them all into one guide structure.
- Figure 7 shows a still further embodiment wherein at least one stop structure 930 such as but not limited to a frit is included on at least one of the extraction channels 808.
- the stop structure 930 is included on the channel 808 coupled to the non- separation member pathway, which may flow more freely and thus have a different flow resistance than the other pathway which passes through the separation member. Venting of the non-separation member pathway channel allows filling via capillary flow.
- the channel 808 is vented through a pointed end of a needle, wherein an air porous frit such as but not limited to one of Porex or similar porous material, is coupled to a tip of needle, still allowing air through, but with more resistance.
- FIG. 71 also shows that in this embodiment, a combined vent 915 can be used to provide a vent path for the various vents associated with the sample distributor over the fluid entry surface of the separation member.
- fill metering can be done using an indicator 950 (see Figure 73) on the non-separation member pathway, because due to its lagging indicator quality due to a slower fill, if a fill level is reached on the non-separation member pathway, due to the slower, fill a user can safely conclude that the other pathway has already completed its fill process due to the slower fill in the non-separation member pathway.
- Figure 73 also shows that there are at least two fluid flow paths within the device as indicated by arrows 951 and 953.
- Figure 73 also shows that there may be guide 955, such as but not limited a guide member in a slot, that may act as a visual indicator that the mo vement of the sample collection unit 824 is complete and may optionally provide sufficient resistance to encourage a controlled rate of movement of the collection unit 824 so that the flow will be sufficient to minimize hemolysis of formed components in the sample.
- guide 955 such as but not limited a guide member in a slot
- Figure 72A it should also be understood that structures without a penetration tip, such a pipette tip, can also be adapted for use with certain embodiments of the sample container.
- Figure 72A also shows that in at least some embodiments, the plunger 828 is only in one vessel and not in all of the vessels defined by the sample container unit.
- Figure 72A may also be shown with the fop plug 832. removed to allow for sample extraction using a pipette tip that is shaped to reach a bottom interior portion of the vessel being emptied.
- this non-limiting example shows a sample container unit 824 with one sample container sized larger to accommodate a pressure drop volume, that is the volume to which air on the plasma side of the formed member separation membrane (including inside the sample container unit) expands due to the pressure drop across the membrane.
- a pressure drop volume that is the volume to which air on the plasma side of the formed member separation membrane (including inside the sample container unit) expands due to the pressure drop across the membrane.
- Figure 75 shows a side view of the device wherein the sample flow pathway indicated by arrow 1010 shows that sample enters at an angle, flows along one plane, downward to a different plane and is drawn laterally out at the lower plane.
- Movement of the sample collection unit 824 is indicated by arrow 1020, wherein in this embodiment, movement of the sample collection unit 824 provides motive force to draw sample substantially free of formed components into the sample collection unit.
- movement of the sample collection unit 824 provides motive force to draw sample substantially free of formed components into the sample collection unit.
- Some embodiments of the collection unit may have a cross-sectional shape with an asymmetry, a protrusion, or other feature that serves as a keying feature for orienting the SCU in any receiving device or structure,
- At least two inlet ports are each defined by at feast one capillary tube.
- each inlet has its own capillary tube
- at least one tube directs fluid to a non- separation pathway while a second tube directs fluid to a separation pathway.
- some embodiments may combine inlets formed by capillary tubes with inlet(s) associated with a non- capillary pathway.
- Some embodiments may have the inlet along a centerline axis of the device.
- some embodiments may have the inlet aligned off the centerline.
- some embodiments may orient the inlet to be along or parallel to the axis of the centerline of the device.
- some embodiments may orient the inlet along an axis that is at an angle to the plane of the device.
- some embodiments may have the inlet directly over at least one portion of the separation device. In this manner, the opening may direct fluid onto the membrane with a minimal amount of travel in a lateral tube or pathway.
- some embodiments may be configured with a co-axial design such as shown in Figure 76.
- One embodiment may have sample enter along an inner lumen for an inside-out type filtration as indicated by arrow 1010.
- some embodiments may use an outside-in type filtration if the separation membrane is located in the inner lumen and sample fluid enters from a surface opening (shown in phantom) as indicated by arrow 1012. or from an infet on one end of the device.
- some embodiments may have a portion 800 such as the fluid circuit portion that includes the separation member fluidly coupled to a second portion 1040.
- a portion 800 such as the fluid circuit portion that includes the separation member fluidly coupled to a second portion 1040.
- it may be configured not to include the non-separation pathway.
- it may be configured to include the non-separation pathway.
- Some embodiments may have this combination of portion 800 with portion 1040 in a test strip configuration.
- Some embodiments may hav e this combination of portion 800 with portion 1040 in a lateral flow device configuration.
- Some embodiments may have a u ibody structure or other merged structure that is formed to provide support to both portions 800 and 1040, Motive force can be provided to move the sample as indicated by arrow 1030 which flow out or the fluid circuit of portion 800 and that the fluid portion of the sample, substantially free of the formed components, can enter a second region 1040 which may be but is not limited to an analytical region.
- the second region 1040 also provides a motive force such as but not limited to wicking force associated with such material in at least a portion of the second region 1040.
- Figure 77B shows a still further embodiment wherein the sample collection device has a plurality of tissue penetrating member or members 1292 mounted to an actuation mechanism 1293.
- the tissue penetrating members 1292 are microneedles. In one embodiment, the tissue penetrating member 1292 comprises a lancet.
- the actuation mechanism 1293 can be a spring-like device in a dome, curved, or other shape. In some embodiments, the dome shape can also provide a certain suction force to draw sample upward from the collection site.
- a mechanical actuation method is shown, it should be understood that other types of actuation tecliniques such as but noi limited to electromechanical, pneumatic, mechanical cam, or other technique known or developed in the future may be used for actuation. It should also be understood that some embodiments may use a tissue interface (shown in phantom) to facilitate interaction with the tissue.
- Figure 77B shows that the sample obtained from a wound or wounds created by tissue penetrating members 1292 may flow through channel(s), capillary tube(s), or other pathways as indicated by arrow 1295 to a channel 1299 or other inlet to a separation device.
- the channel 1299 may be coated with at least one anticoagulant.
- some embodiments may have two channels 1299 that may draw sample along two pathways, wherein each channel may have the same, or optionally different, coatings on the surface of the channels 1299.
- some embodiments may have two channels 1299 that may draw sample along two pathways, wherein each channel may have the same, or optionally different, coatings on the surface of the channels 1299.
- embodiments may have surfaces of the device uncoated but instead have the additive material in the container 1297.
- the sample may flow to a location such as but not limited to a chamber (shown in phantom), one end of the channel 1299 or other location wherein a conduit such as pathway 1301 or 1303 (shown in phantom) may be used to fluidically couple the sample collected in channel 1299 to transfer the sample container 1296 or 1297.
- a conduit such as pathway 1301 or 1303 (shown in phantom) may be used to fluidically couple the sample collected in channel 1299 to transfer the sample container 1296 or 1297.
- Motive force can be provided to move the sample as indicated by arrow 1030 along a horizontal path over the separator, a path from the plane of above the separator to a plane below the separator, and then laterally towards at least one sample container.
- the pathway is a zig-zag path from one side of the separator to the other side which carries the liquid portion to an intermediate chamber or directly to one or more containers.
- the container may be one with a sub atmospheric condition therein (prior to being fluidically engaged to the fluid pathway), one with a reverse syringe design as found in U.S. Provisional Application Ser. No. 62/051 ,906 filed Sept. 17, 2.014, a container may be one that is un-pressurized, without a movable plunger but with a septa cap, or other suitable container for sample as cuiTently known or may be developed in the future.
- ihai some embodiments may have containers 1296 in both locations as shown in Figure 77B or only at one but not the other. Optionally, some may have multiple containers at one location and none or fewer containers at the other location.
- the container 1296 may be actuated by sliding the container 1296 to contact the pathway 301 in a manner that allows sub-atmospheric environment inside the container 1296 to draw sample therein.
- actuation methods such as but not limited to using a valve, breaking a seal, or the like can be used to activate sample transfer from the device to the container 1296.
- Some embodiments may keep the channel 1299 in one horizontal plane or may optionally have portions in one plane and portions in another plane.
- a suction or other sample pulling device can be used to draw sample into the channel 1299.
- the embodiment of Figure 77B may optionally be modified to locate the entry port of channel 1299 closer to the wound site such as but not limited a channel extension 1305, forming the channel closer to the wound site, or positioning or orienting the tissue penetration members to form a wound closer to the inlet of channel 1299.
- devices herein may be configured to include features from U.S. Provisional Application Ser. No. 62/051,906 filed Sept. 17, 2014, fully incorporated herein by reference for all purposes. It should be understood that devices in U.S. Provisional Application Ser. No. 62/051,906 filed Sept. 17, 2014, may be configured to include a formed component separation apparatus as described in this application.
- Figure 77B also shows a still further embodiment using container 1297 having a reverse- syringe design is used. As seen herein, the movement of engaging the container 1297 with pathway 1301 or 1303 can be used to push the plunger 2.828 to create a reduced pressure environment that draws sample into the container 1297. It should be understood that some embodiments may have containers 1297 in both locations as shown in Figure 77B or only at one but not the other. Optionally, some may have multiple containers at one location and none or fewer containers at the other location. Optionally, some of these may be unitized so that multiple vessels are integrally formed or otherwise joined together.
- some embodiments may have one type of container 1296 at one location and a different type of container 1297 at a different location shown in Figure 77B.
- some may have at least two different types of container at one location. Referring still to Figure 77B, some
- embodiments may use a push element 1307 that provide a cap or other seal that when moved as indicated over feature 1305 will cause a pressurized air bolus to push sample in the channel 1299 outward into the containers 1297 that may be attached to 1301 or 1303.
- some embodiments may have at least one formed component separation pathway for use in a non-diagnostic device.
- the device may be for sample collection, where no diagnosis occur on the device.
- some embodiments may have at least one formed component separation pathway and at least one non-separation pathway for use in a nondiagnostic device.
- some embodiments may have at least two formed component separation pathway and at least one non-separation pathway for use in a non-diagnostic device.
- some embodiments may have at least one formed component separation pathway and at least two non-separation pathways, all for use in a non-diagnostic device.
- some alternative embodiments may have one or more pathways for use for diagnosis.
- some embodiments may use this type of separation device with lateral flow strip wherein the fluid, after formed component separation, may be moved such as but not limited to wicking or other capillary flow onto a second region such as but not limited to an analyte-detecting region on a device such as but not limited to a test strip for analysis.
- some embodiments may provide a vibration motion source, such as but not limited to one built into the device and/or in an external device use to process the sample container, to assist in fluid flow within device, during the collection, or post-collection. Some embodiments may use this vibration to assist flow or to remove any air pockets that may be created, such as but not limited to when doing a top-down fill. Optionally, some embodiments may provide more periodic or pulse type force to assist in fluid flow.
- a vibration motion source such as but not limited to one built into the device and/or in an external device use to process the sample container, to assist in fluid flow within device, during the collection, or post-collection.
- Some embodiments may use this vibration to assist flow or to remove any air pockets that may be created, such as but not limited to when doing a top-down fill.
- some embodiments may provide more periodic or pulse type force to assist in fluid flow.
- the fluid collection circuit in portion 800 does not need to be a flat planar device and may be in a curved configuration.
- some embodiments may have it a cone configuration.
- some embodiments may have it device with a polygonal cross-sectional shape. As seen, the fluid collection circuit in portion 800 is not limited to a planar shape.
- the portion 800 may be made of a transparent material.
- the portion 800 may be made of a translucent material.
- portions of the portion 800 may be covered with paint or other opaque material, be formed of an opaque materiai, or the like such that only portions that may contain fluid are transparent or translucent so as to provide an indicator of fill level.
- Such an embodiment may have all or only a portion of the fluidpatli visible to the user.
- bar codes color-coding, visual information, instructions, instructions for use, fill-indicator, advertising, child-appealing aesthetics, texturing, texturing for grip purpose, texturing for contour, texturing to provide feedback such as orientation of the front of the device, or other coating may be used hereon.
- some embodiments may include an intermediary structure between the fluid circuit in portion 800 and the sample collection unit 824.
- This intermediary structure can be in the fluid pathway and provide certain function such as but not limited to introducing a material into the collected fluid such as but not limited to anti-coagulant.
- the mtermediary structure in the fluid paih may provide another route, such as switch or conneciion pathway, to add additional sample or other liquid materiai into the collected fluid.
- some embodiments may have disposable portion(s) and reusable portions, wherein the reusable portions can be mated with the disposable portion(s) to form another collection device.
- a reusable portion may be one that does not directly contact the sample fluid or filtered fluid.
- embodiments herein show the separation member as part of a handheld device, it should be understood that other embodiments may incorporate the device as part of a non-handheld benchtop device, a non-portable device, or the like and the disclosures herein are not limited to handheld or disposable units. Some embodiments may also include features for collection sample from a plurality of sample processing devices. In this manner, an increased amount of filtered sample can be collected, simply by using more de vices for use with more samples which in one embodiment may all be fro one subject. Optionally, samples in multiple devices may be from multiple subjects.
- the phrase “substantially different”, as used herein, denotes a sufficiently high degree of difference between two numeric values such that one of skill in the art would consider the difference between the two values to be of statistical significance within the context of the characteristic measured by said values.
- the difference between two values that are substantially different from each other is typically greater than about 10%, and may be greater than about 20%, preferably greater than about 30%, preferably greater than about 40%, preferably greater than about 50% as a function of the reference value or comparator value.
- a "surfactant” is a compound effective to reduce the surface tension of a liquid, such as water.
- A. surfactant is typically an amphophilic compound, possessing both hvdrophilic and hydrophobic properties, and may be effective to aid in the solubilization of other compounds.
- a surfactant may be, e.g., a hvdrophilic surfactant, a lipophilic surfactant, or other compound, or mixtures thereof.
- Some surfactants comprise salts of long-chain aliphatic bases or acids, or hydrophilic moieties such as sugars.
- Surfactants include anionic, cationic, zwitterionic, and non-ionic compounds (where the term “non-ionic” refers to a molecule that does not ionize in solution, i.e., is “ionically” inert).
- surfactants useful in the reagents, assays, methods, kits, and for use in the devices and systems disclosed herein include, for example, Tergitol TM nonionic surfactants and Dowfax TM anionic surfactants (Dow Chemical Company, Midland, Michigan 48642); polysorbates (polyoxyethylenesorbitans), e.g., polysorbate 2.0, polysorbate 80, e.g., sold as TWEEN ® surfactants (ICI Americas, Ne Jersey, 08807); poloxamers (e.g., ethylene oxide/propylene oxide block copolymers) such as Pluronics ® compounds (BASF, Florham Park, N.J); polyethylene glycols and derivatives thereof, including Triton TM surfactants (e.g., Triton 1* ' X-100; Dow Chemical Company, Midland, Michigan 48642) and other polyethylene glycols, including PEG- 10 laurate, PEG- 12.
- Triton TM surfactants e.g.
- phosphatidylcholine phosphatidylethanolamine, phosphatidylglycerol, phosphatidic acid, phosphaiidyiserine; lysolecithins and hydrogenated lysolecithins: phospholipids and derivatives thereof; lysophosphoHpids and derivatives thereof, including lysophosphatidylclioline, lysophosphatidylethanoi amine, lysophosphatidy ⁇ glycerol, fysophosphatidic acid,
- carnitine fatty acid ester salts salts of alkyisulfates; fatty acid salts; sodium docusate; acyl lacry lates; mono- and di-acetylated tartaric acid esters of mono- and di-glycerides; succinylated mono- and di-glycerides; citric acid esters of mono- and di-gfycerides; lactylic esters of fatty acids, stearoyl-2-lactyiate, stearoyl lactylate, succinylated monoglycerides, mono/diacetylated tartaric acid esters of mono/diglycerides, citric acid esters of mono/digJycerides, cholylsarcosine, caproate, caprylate, caprate, iaurate, myristate, paimitate, oleate, ricinoleate, linoleate, linolenate, stearate, la ryl s
- Figure 78 shows a side cross -sectional view of the separation material 3100, showing cross-sections of the structures 3102 of the separation material.
- the separation material 3100 may be a size-exclusion barrier such as but not limited to a porous membrane with size-exclusion properties. Other embodiments may use other types of size-exclusion barrier(s).
- the structures 3102 are fibers in the separation material with their cross-sectional views shown in Figure 78.
- the structures 3102 are mesh portions of the separation material.
- the structures 3102 are pore walls or pore-defining structures of the separation material.
- the structures 3102 may be a percolating network of connected fibers, elongate members, or the like. Some embodiments may combine one or more of the foregoing to form the separation material.
- FIG. 78 shows that for the present embodiment, formed components 3106 such as but not limited to red blood cells, white blood cells, platelet, or other formed components of the bodily fluid can enter the separation material 3100 in a variety of directions, including from a top-down manner, and will continue to pass through the separation material until the component reaches a size-constrained area where the spacing becomes too small for the formed component 3106 to proceed any further, in this embodiment, operating under the principle of size exclusion, the formed component 3106 will then be constrained in the separation material 3100 while liquid portions and/or those components not size excluded can continue to pass through the separation material.
- formed components 3106 such as but not limited to red blood cells, white blood cells, platelet, or other formed components of the bodily fluid can enter the separation material 3100 in a variety of directions, including from a top-down manner, and will continue to pass through the separation material until the component reaches a size-constrained area where the spacing becomes too small for the formed component 3106 to proceed any further, in this embodiment, operating under the principle of size
- arrows 3104 show movement of formed components through the separation material 3100 of Figure 78.
- Other movement such as but not limited to lateral, side-ways, and/or diagonal movement, is not excluded.
- the dotted line 3120 shows that in this embodiment, there are at least two regions 3122 and 3124 for the separation material 3100. It should be understood that other embodiments can have even more regions.
- the region 3122 comprises a formed component capture region. In some specific embodiments as will be discussed in more detail below, it may be an anti- hemolytic, formed component capture region.
- the region 3124 comprises a pass- through region that has structural elements spaced closely enough that formed components of the bodily fluid sample cannot completely pass through that region 312.4.
- the sizing and/or spacing of elements is selected such that the size-restriction technique of separation material components prevents the formed components from continuing through the separation material. This filters out the formed components from the liquid components of the bodily fluid.
- region 3122 can be configured to be a formed component capture region
- structures in the region 3122 will have more potential direct contact with the formed components 3106 and be in contact w ith them for a longer period of time, relative to structures in the second region 3124. Due at least in part to the greater direct contact physically and temporally, it may be desirable in it at least some embodiments described herein to treat the structures 3102 of the region 3122 to minimize undesirable breakdown, spoilage, or other detrimental effect thai may result from the formed components being captured in the region 3122.
- the structures 3102 may be coated with an anti-hemolytic coating to prevent breakdown of red blood cell when the bodily fluid being processed is blood.
- an anti-hemolytic coating may be an NT A. coating.
- other anti- hemolytic treatments in layer or other form may use material such as but not limited to n-Qctyl- ⁇ -D-Glucopyranoside (OG), cell lipid bilayer intercalating material, phosphate ester containing at least two ester linkages comprising fatty hydrocarbon groups, tri-2-ethylhexylphosphate, di-2- ethyihexylphthalate, diocrylterephthalate, anti-hemolytic surfactant(s), a surfactant such as but not limited to polysorbate 80 mixed with any of the foregoing, and/or other anti-hemolytic material.
- OG n-Qctyl- ⁇ -D-Glucopyranoside
- phosphate ester containing at least two ester linkages comprising fatty hydrocarbon groups tri-2-ethylhexylphosphate, di-2- ethyihexylphthalate, dioc
- anti-hemolytic material used with embodiments herein includes but is not limited to one or more of the following: anti-coagulants, proteins (such as but not limited to BSA, HSA, Heparin, Casein, etc.), surfactants (such as but not limited to Tween, Silwet, SDS, etc.), sugars (such as but not limited to sucrose, trealose, etc.), and/or the like.
- anti-coagulants proteins (such as but not limited to BSA, HSA, Heparin, Casein, etc.), surfactants (such as but not limited to Tween, Silwet, SDS, etc.), sugars (such as but not limited to sucrose, trealose, etc.), and/or the like.
- the region 3124 may be configured to be a liquid pass- through region positioned after the bodily fluid has passed through region 3122.
- Figure 78 illustrates region 3124 to be next to region 3122, it should be understood that embodiments having intermediate region(s) and/or space between the regions are not excluded.
- the pass- through region 3124 may be configured not have direct contact with the formed components.
- only structures 3108 defining part of the upper portion of the region 3124 may be in contact with any formed components 3106.
- the region 312.4 may be have a selected structure size, spacing, and/or other property that prevents formed components 3106 from passing through the region 3124 so as to enable a size restriction filtering technique for removing formed components from the bodily sample.
- the separation material of region 3124 may not be coated with the material used in the region 3122.
- region 3124 may be selective coated with the materials used in region 3122 in a manner such as but not limited to only those portions that might still be in contact with formed components may ⁇ be coated, which others portions of region 3122 are uncoated.
- at least some embodiments may have some or all of region 3124 coated with a material different from that of the region 3122.
- at least some embodiments may have some or all of region 3124 covered with the material of region 3122 and then adding a second layer of the second material over the material of region 312.2.
- this second material may be selected to prevent the first material leaching or otherwise entering the bodily fluid when the liquid passes through the region 3124.
- the portions of region 3124 covered with the material of region 3122 is covered with the second material while other areas of region 3124 are substantially or at least partially uncovered by either material.
- some embodiments may use Heparin and/or other anti-coagulant as the material for the second layer.
- the material for the second layer may be a material that is already in the bodily fluid sample.
- the material may be EDTA if the bodily fluid sample has already been or will be treated with EDTA.
- some embodiments may use inert materials alone or in combination with any of the other materials listed herein.
- FIG. 79 shows a still further embodiment.
- This embodiment shows a first separation material 32.00 and a second separation material 32.10. Although only two separation materials are shown, it should be understood that other embodiments having additional separation materials above, between, and/or below the separation materials shown in Figure 79 are not excluded. It should also be understood that one or more of
- the separation materials 3200 and 3210 can, within the separation materials themselves, each have additional regions therein for different properties.
- the separation material 200 functions as a capture region similar to the capture region 3122 of the embodiment of Figure 78.
- the separation material 3210 functions as a pass-through region similar to region 3124 of the embodiment of Figure 78.
- this embodiment shows a tri-layer filter assembly with a first lay er 3300, a second layer 3310, and a third layer 3320.
- the layers are shown to be similar in thickness, but configurations where all three are of different thicknesses, or only are of different thicknesses are not excluded. Embodiments with additional layers are also not excluded. Layers can also be formed of different materials.
- any of the layers 3300, 3310, or 3320 can be configured as a capture region, a pass-through region, or neither.
- at least the upper two layers 3300 and 3310 are capture regions. They can have similar capture capabilities, or optionally, one can be configured to be preferential capture of components while the other layer has preferential capture of components in a different size and/or shape regime.
- at least the upper two layers 3300 and 3310 are captures regions, but only one of them is coated with a material to prevent degradation of the formed components).
- both of them are coated with a material to prevent degra dation of the formed components).
- Another embodiment may have two layers such as layers 3310 and 3320 that are both configured as pass-through layers.
- neither of the layers 3310 or 3320 have structures that are coated with a material to prevent degradation of the formed component(s).
- at least one of the layers 3310 or 3320 has structures that are coated with a material to prevent degradation of the formed component(s).
- some embodiments have both of the layers 3310 or 3320 have structures that are coated with a material to prevent degradation of the formed component(s).
- separation material treatment methods in order to be able to use separation materials for producing plasma suitable for a greater range of assays, several separation material treatment methods have been identified. Some of these techniques may involve treatment of separation materials after they are formed. Some of the techniques may involve forming the separation materials in a way that does not involve additional treatment after separation material formation. Optionally, some techniques may use boih separation material formation and post- formation treatment to create a desired configuration.
- FIG. 81 shows that a washing mechanism, such as but not limited to a nozzle 3400 directing washing fluid (as indicated by the arrows) towards the target separation material 3402, can be used to reduce at least some of the coating off of the separation material. This can create a preferential change in the amount of coating in selected areas of the separation material.
- a washing mechanism such as but not limited to a nozzle 3400 directing washing fluid (as indicated by the arrows) towards the target separation material 3402, can be used to reduce at least some of the coating off of the separation material.
- a washing mechanism such as but not limited to a nozzle 3400 directing washing fluid (as indicated by the arrows) towards the target separation material 3402, can be used to reduce at least some of the coating off of the separation material. This can create a preferential change in the amount of coating in selected areas of the separation material.
- One example may show removal or at least reduction of coating on one side of the separation material.
- some may direct the wash fluid to wash coating off of an interior
- a carefully controlled washing is desirable so as to not completely remove the hemolysis preventing agent - which would result in hemolysis.
- insufficient wash will result in sufficient amount of the hemolysis preventing agent leaching into the plasma and causing hemolysis.
- a reduced amount of coating, or coating in interior portions of the separation material can be acceptable.
- some embodiments may also use a bath 3410 of wash fluid that preferentially removes coating material from certain areas of the separation material.
- spray washing and bath soaking, or vice versa may be combined for use on a separation material. This processing may occur sequentially or simultaneously.
- both coated and uncoated versions of the plasma separation material can be coated using a custom formulation which is compatible with assay chemistries.
- the coating may contain one or more of the following: proteins, surfactants, sugars, organic and inorganic salts, anti-coagulants, etc.
- the coating could be applied to an initially un-coated separation material to prevent hemolysis.
- an initially coated separation material may ⁇ be further coated to prevent assay interfering substances from leaching into the bodily fluid from the separation material.
- separation material surface charge can be neutralized to prevent retention of small, oppositely charged ions.
- the separation material with NTA coating has a negatively-charged surface, which can be neutralized to prevent retention of positi vely charged Ca++ ions.
- a coating has a positively-charged surface and is in turn attracting negatively charged ions in a detrimental manner, the member will be treated to neutralize the undesired charge condition.
- ⁇ 22 ⁇ 4.
- Other techniques and/or materials may also be used to create a filter such as a separation material that has anti-hemo lytic qualities on the capture surfaces of the filter and non- leaching qualities on other surfaces of the filter.
- Some embodiments may combine one or more of the foregoing techniques on a separation material.
- one embodiment may have coated and uncoated regions on a separation material along with having been treated to achieve charge neutralization before, during, and/or after coating.
- asymmetric membranes were washed with high performance liquid chromatography (HPLC) grade water and then tested.
- the membrane has a pore volume of 2 ⁇ _ ⁇ per 10mm 2 of membrane.
- the pore loading is defined as the ratio of the total volume of blood to the pore volume.
- the wash procedure comprised pre-mounting membrane in a fixture for filtration. In this particular example, about 600 uL of water is directed through the membrane and then the water is discarded. This wash process of directing water through the membrane was repeated, which in this particular example, involved repeating the wash five (5) times. After washing, the membranes are allowed to dry. Filtration of the dynamically washed membranes were then tested.
- washing by way of soaking can create differences in the performance of the resulting membrane.
- anti-hemolytic is preferentially removed from the large pore region.
- anti-hemolytic is preferentially remo ved from the small pore region. This asymmetry in coating material may be desirable when the formed blood components contact the membrane where the pores are larger while only plasma contacts the smallest pores. Hemolysis prevention happens only in the regions where RBCs can enter or be contacted (i.e. the large pore region). It is not possible to hemolyze plasma and thus coating the small pore region with anti-hemolytic does not result in noticeable performance benefit. As noted herein, the excess anti-hemolytic may have adverse impact on assay results for the assays sensitive to excess anti-hemolytic coating.
- shear dominates removal of anti-hemolytic. Shear increases dramatically with decreasing diameter. Without being bound to any particular theory, total removal should be greater in small pore regions, where shear is most significant.
- the coating on the membrane can be a material that provides a negative charge.
- a negative charge repels formed blood component that have a negative polarity, and thereby reduces mechanical trauma inflicted on such formed blood components via contact with the membrane during filtration.
- Some embodiments may use formulations with negatively charged substances to coat all or optionally selective areas on the membrane.
- One embodiment may use casein 0.5%, Tween 20 1.35%, sucrose 5%, 15 minute soak time.
- one embodiment may use Li- Heparin 50mg/mL, sucrose 5%.
- one embodiment may use Li-Heparin 50mg/mL, Tween 80 1 .35%, sucrose 5%.
- one embodiment may use Casein 1.0%, Tween 20 2.70%, sucrose 5%.
- one embodiment may use Li-Heparin 100 mg/ ' niL, Tween 20 2.70%, sucrose 5%.
- Figure 83 shows a bodily fluid sample B on a skin surface S of the subject.
- the bodily fluid sample B can be coll ected by one of a variety of devices.
- collection device 1530 may be but is not limited to those described herein, in the present embodiment, the bodily fluid sample B is collected by one or more capillary channels and then directed into sample vessels 1540.
- the sample B forms through a wound that may be formed on the subject. This may be by way of fingerstick or wound created at other alternate sites on the body.
- a lancet, a needle, other penetrating device, or other technique may be used to release the bodily fluid sample from the subject.
- at least one of t e sample vessels 1540 may have an interior that is initially under a partial vacuum that is used to draw bodily fluid sample into the sample vessel 1540.
- Some embodiments may simultaneously draw sample from the sample collection device into the sample vessels 1540 from the same or different collection channels in the sample collection device.
- some embodiments may simultaneous draw sample into the sample vessels.
- the sample vessels 1540 in their holder 1542 may placed in the sample verification device or directly into a storage device in a temperature controlled environment.
- the sample vessels 1540 in their holder 1542 are loaded into the transport container 1500.
- one of the sample vessels 1540 may contain only liquid portions of the sample (no formed blood components) which the other may contain sample with both liquid portion and formed component portion.
- at least two of the sample vessels 1540 may contain only liquid portions of the sample (no formed blood components).
- they may hold the sample vessels in an arrayed configuration and oriented to be vertical or some other pre-determined orientation.
- some embodiments of the sample vessels 1540 are configured so that they hold different amount of sample in each of the vessels.
- this can be controlled based on the amount of vacuum force in each of the sample v essels, the amount of sample collected in the sample collection channels) of the collection device, and/or other factors.
- different pre-treatments such as but not limited to different anti-coagulants or the like can also be present in the sample vessels.
- the sample vessels 1540 are collecting sample at a first location such as but not limited to a sample collection site.
- the bodily fluid samples are then transported in the transport container 1500 to a second location such as but not limited to an analysis site.
- the method of iransport may be by courier, postal delivery, or other shipping technique.
- the transport may be implemented by having a yet another container that holds the transport container therein.
- the sample collection site may be a point-of-care.
- the sample collection site is a point-of-service.
- the sample collection site is remote from the sample analysis site.
- FIG. 83 shows the collection of bodily fluid sample from a surface of the subject
- other alternative embodiments may use collection techniques for collecting sample from other areas of the subject, such as by venipuncture, to fill the sample vessei(s) 1540, Such other collection techniques are not excluded for use as alternative to or in conjunction with surface collection.
- Surface collection may be on exterior surfaces of the subject.
- some embodiments may collect from accessible surfaces on the interior of the subject. Presence of bodily fluid sample B on these surfaces may be naturally occurring or may occur through wound creation or other techniques to make the bodily fluid surface accessible.
- the fluid sample may be whole blood, diluted blood, interstitial fluid, sample collected directly from the patient, sample that is on a surface, sample after some pre-treatment, or the like.
- embodiments herein are described in the context of an anti-liemolytic coating, it should be understood that these embodiments may also be configured for use with other types of coatings, including but not limited to other coatings which may undesirably mix into the bodily fluid upon prolonged fluid exposure.
- Other material used with embodiments herein may include but is not limited to one or more of the following: anti-coagulants, proteins (BSA, HSA, Heparin, Casein, etc.), surfactants (Tween, Silwet, SDS, etc.), sugars (sucrose, trealose, etc.).
- coatings of one or more of the following may be used to coat portions of fluid pathways of the device, only the channels of the distributor, only the non-channel portions of the distributor, sample collection areas, sample distributor area(s), channels, tubes, chambers, or other features of the device with: anti-hemolytic, anti-coagulants, proteins (BSA, HSA, Heparin, Casein, etc.), surfactants (Tween, Silwet, SDS, etc), sugars (sucrose, trealose, etc.), or other coatings.
- a bodily fluid separation material comprising a formed component capture region and a bodily fluid pass-through region.
- the pass-through region has structures with a reduced liquid leaching quality relative to than the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region.
- a bodily fluid pass-through region has a reduced amount of liquid leaching material relative to than the capture region.
- a bodily fluid separation material comprising an anti-hemolytic and formed component capture region; and a bodily fluid pass-through region having less anti-hemolytic materiai than the capture region, wherein during separation material use, bodily fluid enters the capture region prior to entering the pass-through region.
- a bodily fluid separation material comprising a first filter region of the separation material having an anti-hemolytic coating and mesh spacing sized to constrain formed blood components therein; a second filter region of the separation material having mesh spacing smaller than mesh spacing of the first filter region and configured to have an amount of anti-hemolytic coating less than that of the first region.
- a bodily fluid separation material comprising a percolating network of structures wherein a first region of the percolating network with an anti-hemoiytic coating on structures in the region, said structures sized and spaced to allow formed blood components to enter the first region but constraining blood components therein from passmg completely through the first region; and a second region of the percolating network with a reduced anti-hemolytic coating on structures sized and spaced to prevent formed blood components from entering the second region, wherein bodily fluid passes through the first region prior to reaching the second region.
- the separation material may be an asymmetric separation material.
- the anti-hemolytic material on the separation material comprises single and/or double alky] chain N-oxides of tertiary amin es (NTA).
- NTA tertiary amin es
- the first region comprises a first separation material layer and the second region comprises a second separation material layer.
- the separation material comprises a first separation material coupled to a second separation material.
- the separation material comprises at least two separate separation materials.
- the first region of the separation materiai may be in fluid communication with the second region.
- the first region may be spaced apart from the second region.
- a method for forming a bodily fluid separation material comprises coating the separation materiai with an anti-hemolytic coating on a first region and a second region of the separation material; reducing anti- hemolytic effect of the second region of the separation material relative to the first region, wherein when the separation material is in operation, bodily fluid passes through the first region prior to reaching the second region.
- the method may include reducing the anti- hemo lytic effect by washing off at least a portion of the anti-hemolytic coating on the second region.
- washing off comprises directing solvent through the separation material.
- washing off comprises soaking only a portion of the separation material in a sol v ent.
- reducing the anti-hemolytic effect comprises adding another coating of a different material over the anti-hemoK'tic coating on the second region.
- reducing the anti- hemolytic effect comprises treating the separation material to bring its electrical charge state to a neutral state and thus reduce the attraction of ions that increase the anti-hemolytic effect.
- a method for forming a bodily fluid separation material.
- the method comprises coating at least a first region of the separation material with an anti-hemolytic coating; not coating at leas t second region of the separation material with the anti-hemolytic coating.
- some embodiments have a bilayer structure based on a substantially even coating of anti-hemolytic material, but instead has a region of substantially greater pore size than another region.
- the material may be asymmetric, it is a not a linear gradient, but instead has a rapid change in pore size at an inflection point when pore size is graphed in depth from top of the layer to bottom of the layer.
- a size range of about 1 nm to about 200 nm should be interpreted to include not only the explicitly recited limits of about 1 nm and about 200 nm, but also to include individual sizes such as 2 nm, 3 nm, 4 nm, and sub-ranges such as 10 nm to 50 nm, 20 nm to 100 nm, etc.
- Patent 8,380,541 U.S. Pat. App. Ser. No. 13/769,798, filed February 18, 2013; U.S. Pat. App. Ser. No. 13/769,779, filed February 18, 2013; U.S. Pat. App. Ser. No. 61/766,1 13 filed February 18, 2013, U.S. Pat. App. Ser. No. 13/244,947 filed Sept. 26, 201 1 ; PCT7US2012/57155, filed September 25, 2012; U.S. Application Serial No.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Analytical Chemistry (AREA)
- Clinical Laboratory Science (AREA)
- Dispersion Chemistry (AREA)
- Ecology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Sampling And Sample Adjustment (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Automatic Analysis And Handling Materials Therefor (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461948542P | 2014-03-05 | 2014-03-05 | |
US201461952112P | 2014-03-12 | 2014-03-12 | |
PCT/US2014/030070 WO2014145330A2 (en) | 2013-03-15 | 2014-03-15 | Methods and devices for sample collection and sample separation |
US201462051929P | 2014-09-17 | 2014-09-17 | |
PCT/US2015/019060 WO2015134809A1 (en) | 2014-03-05 | 2015-03-05 | Methods and devices for sample collection and sample separation |
Publications (3)
Publication Number | Publication Date |
---|---|
EP3114451A1 true EP3114451A1 (en) | 2017-01-11 |
EP3114451A4 EP3114451A4 (en) | 2017-09-27 |
EP3114451B1 EP3114451B1 (en) | 2022-10-19 |
Family
ID=54055891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15757840.2A Active EP3114451B1 (en) | 2014-03-05 | 2015-03-05 | Device for sample separation |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3114451B1 (en) |
JP (3) | JP2017507335A (en) |
CN (2) | CN106574883B (en) |
CA (1) | CA2941009C (en) |
MX (1) | MX2016011474A (en) |
WO (1) | WO2015134809A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9386948B2 (en) | 2012-12-05 | 2016-07-12 | Theranos, Inc. | Systems, devices, and methods for bodily fluid sample transport |
US10248765B1 (en) | 2012-12-05 | 2019-04-02 | Theranos Ip Company, Llc | Systems, devices, and methods for bodily fluid sample collection, transport, and handling |
WO2014145330A2 (en) | 2013-03-15 | 2014-09-18 | Theranos, Inc. | Methods and devices for sample collection and sample separation |
US10371606B2 (en) | 2015-07-21 | 2019-08-06 | Theraos IP Company, LLC | Bodily fluid sample collection and transport |
US10906042B2 (en) * | 2015-07-21 | 2021-02-02 | Gattaco Inc. | Automatic plasma separation and metering |
US11247208B2 (en) | 2015-09-09 | 2022-02-15 | Labrador Diagnostics Llc | Methods and devices for sample collection and sample separation |
US11857966B1 (en) | 2017-03-15 | 2024-01-02 | Labrador Diagnostics Llc | Methods and devices for sample collection and sample separation |
US11738347B2 (en) | 2017-08-24 | 2023-08-29 | Innatoss Laboratories B.V. | Liquid handling system and method |
FR3076206B1 (en) * | 2017-12-30 | 2023-04-21 | Clariant Healthcare Packaging France Sas | CONTAINER FOR MEDICAL AND/OR PHARMACEUTICAL PRODUCTS WITH GAP |
US20220287689A1 (en) * | 2019-08-06 | 2022-09-15 | Purewick Corporation | Fluid collection assemblies including a sample port |
CN111337481B (en) * | 2020-04-26 | 2024-07-09 | 成都斯马特科技股份有限公司 | Chemiluminescence immunity analyzer |
CN114486351B (en) * | 2022-01-06 | 2024-06-04 | 平顶山市慧鑫源生物科技有限公司 | Animal fat multipoint sampling equipment with cholesterol detects |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4761381A (en) * | 1985-09-18 | 1988-08-02 | Miles Inc. | Volume metering capillary gap device for applying a liquid sample onto a reactive surface |
WO1996035952A1 (en) * | 1995-05-09 | 1996-11-14 | Smithkline Diagnostics, Inc. | Devices and methods for separating cellular components of blood from liquid portion of blood |
US6074827A (en) * | 1996-07-30 | 2000-06-13 | Aclara Biosciences, Inc. | Microfluidic method for nucleic acid purification and processing |
TW391881B (en) * | 1996-09-25 | 2000-06-01 | Baxter Int | Method and apparatus for filtering suspensions of medical and biological fluids or the like |
US6806543B2 (en) * | 2002-09-12 | 2004-10-19 | Intel Corporation | Microfluidic apparatus with integrated porous-substrate/sensor for real-time (bio)chemical molecule detection |
JP2004212250A (en) * | 2003-01-06 | 2004-07-29 | Sekisui Chem Co Ltd | Specimen collection tool |
WO2005079985A1 (en) * | 2004-02-17 | 2005-09-01 | Ibidi Gmbh | Device for microfluidic analyses |
ATE385572T1 (en) * | 2004-03-05 | 2008-02-15 | Egomedical Swiss Ag | ANALYTE TEST SYSTEM FOR DETERMINING THE CONCENTRATION OF AN ANALYTE IN A PHYSIOLOGICAL LIQUID |
JP2006058280A (en) * | 2004-03-16 | 2006-03-02 | Fuji Photo Film Co Ltd | Assay chip |
US20070178521A1 (en) | 2004-03-16 | 2007-08-02 | Yoshiki Sakaino | Assay chip |
US8158410B2 (en) * | 2005-01-18 | 2012-04-17 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
US8206650B2 (en) * | 2005-04-12 | 2012-06-26 | Chromedx Inc. | Joint-diagnostic spectroscopic and biosensor meter |
JP4656992B2 (en) * | 2005-04-14 | 2011-03-23 | 積水化学工業株式会社 | Micro filter unit |
EP1970006A1 (en) * | 2007-03-14 | 2008-09-17 | Roche Diagnostics GmbH | Analysis system for determining a analyte in a body fluid and disposable integrated sample extraction and analysis element |
CA3138078C (en) | 2007-10-02 | 2024-02-13 | Labrador Diagnostics Llc | Modular point-of-care devices and uses thereof |
SG181676A1 (en) * | 2009-12-23 | 2012-07-30 | Cytovera Inc | A system and method for particle filtration |
US8480978B2 (en) * | 2010-08-12 | 2013-07-09 | University Of Southern California | Microfluidic fluid separator and related methods |
CN102350379A (en) * | 2011-07-04 | 2012-02-15 | 大连理工大学 | Micro fluid control whole blood preprocessing chip based on naturally-deposited filling column |
US8380541B1 (en) | 2011-09-25 | 2013-02-19 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US9675755B2 (en) | 2012-04-04 | 2017-06-13 | National Scientific Company | Syringe filter |
-
2015
- 2015-03-05 EP EP15757840.2A patent/EP3114451B1/en active Active
- 2015-03-05 CA CA2941009A patent/CA2941009C/en active Active
- 2015-03-05 WO PCT/US2015/019060 patent/WO2015134809A1/en active Application Filing
- 2015-03-05 MX MX2016011474A patent/MX2016011474A/en unknown
- 2015-03-05 CN CN201580021952.4A patent/CN106574883B/en active Active
- 2015-03-05 CN CN202111243568.2A patent/CN113796860A/en active Pending
- 2015-03-05 JP JP2016555595A patent/JP2017507335A/en not_active Withdrawn
-
2020
- 2020-03-19 JP JP2020049102A patent/JP2020095057A/en not_active Withdrawn
-
2022
- 2022-02-17 JP JP2022022795A patent/JP2022060360A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN106574883A (en) | 2017-04-19 |
CA2941009A1 (en) | 2015-09-11 |
EP3114451B1 (en) | 2022-10-19 |
WO2015134809A1 (en) | 2015-09-11 |
JP2017507335A (en) | 2017-03-16 |
EP3114451A4 (en) | 2017-09-27 |
CN106574883B (en) | 2021-11-12 |
JP2022060360A (en) | 2022-04-14 |
JP2020095057A (en) | 2020-06-18 |
MX2016011474A (en) | 2016-11-16 |
CA2941009C (en) | 2023-09-26 |
CN113796860A (en) | 2021-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9908113B2 (en) | Methods and devices for sample collection and sample separation | |
US20210370297A1 (en) | Devices for sample collection and sample separation | |
EP3114451B1 (en) | Device for sample separation | |
US20150273467A1 (en) | Methods and devices for sample collection and sample separation | |
US20140323911A1 (en) | Methods and devices for sample collection and sample separation | |
EP2986384B1 (en) | Biological fluid sampling transfer device and biological fluid separation and testing system | |
EP2986381B1 (en) | Biological fluid collection device and biological fluid separation and testing system | |
US20140309556A1 (en) | Biological Fluid Collection Device and Biological Fluid Collection and Testing System | |
EP2986380B1 (en) | Biological fluid sampling, separation and testing system | |
US11857966B1 (en) | Methods and devices for sample collection and sample separation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20161004 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20170828 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61B 5/154 20060101ALI20170822BHEP Ipc: A61J 1/05 20060101AFI20170822BHEP Ipc: A61B 10/00 20060101ALI20170822BHEP Ipc: A61B 5/15 20060101ALI20170822BHEP Ipc: G01N 1/00 20060101ALI20170822BHEP Ipc: A61B 5/153 20060101ALI20170822BHEP Ipc: A61J 1/14 20060101ALI20170822BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THERANOS, INC. |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: THERANOS IP COMPANY, LLC |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20181031 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LABRADOR DIAGNOSTICS LLC |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20200911 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTC | Intention to grant announced (deleted) | ||
INTG | Intention to grant announced |
Effective date: 20210511 |
|
GRAJ | Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted |
Free format text: ORIGINAL CODE: EPIDOSDIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
INTC | Intention to grant announced (deleted) | ||
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20220127 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602015081237 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1525136 Country of ref document: AT Kind code of ref document: T Effective date: 20221115 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20221019 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1525136 Country of ref document: AT Kind code of ref document: T Effective date: 20221019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230220 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230119 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230219 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20230120 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602015081237 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 |
|
26N | No opposition filed |
Effective date: 20230720 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602015081237 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230305 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230305 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230305 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230305 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230305 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231003 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20221019 |